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AST  Attention switching task 
Bid  twice daily 
BP  blood pressure 
bpm   beats per minute 
CANTAB Cambridge Neuropsychological Test Automated Battery 
CBF  cerebral blood flow 
CBFv  cerebral blood flow velocity 
CENTRAL  Cochrane Central Register of Controlled Trials 
CI  confidence interval 
CNHSQ Children’s National Health System Questionnaire 
COMPASS composite autonomic symptom score 
DBP  Diastolic blood pressure 
EDV  End diastolic velocity 
EPO  erythropoietin 
ETCO2  End tidal carbon dioxide  
FeSo4  ferrous sulfate 
fMRI  functional magnetic resonance imaging 
HPA axis hypothalamus-pituitary-adrenal axis 
HR  heart rate 
HUTT  Head up tilt test 
IBS  irritable bowel syndrome 
IV  intravenous 
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IM  intramuscular 
IQR  Interquartile range 
LAR  long-acting release 
MAP  Mean arterial pressure 
MCA  middle cerebral artery 
MRI  Magnetic resonance imaging  
NA  not available 
NET  norepinephrine transporter 
NIRS  Near infrared spectroscopy 
NVC  Neurovascular coupling 
OD  once daily 
OH  Orthostatic hypotension 
OHQ  Orthostatic Hypotension Questionnaire 
OHDAS Orthostatic hypotension daily activity scale 
OHSA  Orthostatic hypotension symptom assessment 
OI  orthostatic intolerance 
PCA  posterior cerebral artery 
POTS  posterior orthostatic tachycardia syndrome 
PRISMA  Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
PSV  Peak systolic velocity 
QOL  quality of life 
RCT  randomised controlled trial 
RR  Respiratory rate 
RT  Reaction time 
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RVIP  Rapid visual information processing  
SC  subcutaneous 
SCI  Spinal cord injury 
SF-36  Short form 36 questionnaire 
SQ(n)  symptom questionnaire rating on (n) symptoms 
SR  slow release 
TAP  Time averaged peak 
TCD  transcranial Doppler ultrasound 
Tid  3 times per day 
WFDI  Walker Functional Disability Inventory 




Thesis Aims and Outline 
 
 
 Postural tachycardia syndrome (POTS) is a chronic debilitating condition characterized by 
symptoms of light-headedness, fatigue, palpitations, pre-syncope, sleep disturbances, cognitive 
impairment and brain fog in conjunction with an exaggerated increase in heart rate (HR) when 
upright, despite maintenance of a normal blood pressure (BP). There is little high-level 
evidence to inform current guidelines for the investigation and management of POTS, at least 
in part due to the lack of biological markers to provide clarity on diagnosis and to quantify 
severity of disease. The objectives of the work described in this thesis was to highlight the 
gaps in evidence for therapeutic modalities currently available for the treatment of patients 
with POTS  and to study the value of transcranial doppler (TCD) measures of cerebral blood 
flow velocity (CBFv) during orthostatic and cognitive stress for future therapeutic trials in 
patients with POTS. The rationale behind use of TCD measurement of CBFv relates to the 
hypothesis that periodic reduction in cerebral blood flow (CBF) due to inadequate 
compensation for changes in orthostatic pressure may explain the almost universal symptom 
of mental clouding described by patients with POTS. Since many patients with POTS describe 
mental clouding even when recumbent, we hypothesized that regulation of CBF in response 
to cognitive activation in the absence of orthostatic stress may also be dysfunctional. We 
therefore studied CBF during both orthostatic and cognitive stress in patients with POTS. 
 
 An overview of the pathophysiology and co-morbidities associated with POTS is 
provided in Chapter 1 followed by a systematic review of the efficacy and quality of evidence 
for therapies currently utilised in the management of patients with POTS (Chapter 2). The 
results of our pilot study of CBFv in patients with POTS, and controls, is reported in Chapter 3. 




In our pilot study, the effect of a visual stimulus on CBFv was measured using a handheld 
duplex TCD. We replicated the methodology previously used to demonstrate a reduction in 
neurovascular coupling (as demonstrated by a reduced CBFv response to a visual stimulus) in 
a study of patients with spinal cord injuries. (1) The rationale for replicating this methodology 
was the authors’ attribution of the reduced neurovascular coupling in patients with spinal cord 
injury to disruption in the patients’ autonomic feedback loops. As autonomic dysfunction has 
long been suspected to underlie the pathophysiology of POTS,(2) we considered the robust 
findings generated through the relatively simple methodology described by Phillips might 
prove useful in the study of patients with POTS. Unfortunately, this was not the case. Instead, 
we found similar changes in CBFv in our patient and control groups in response to the brief 
visual stimulus.  
As a result of the negative findings from our pilot study (in which a brief visual stimulus was 
used), in subsequent studies we measured changes in CBFv during a prolonged cognitive 
stress. Not only was this stimulus a better reflection of the conditions during which patients 
typically experienced “brain fog” but it also allowed us to measure the effect of fatigue on 
symptoms scores, CBFv responses, and on cognitive performance.  
 
As a result of difficulty in maintaining the angle of insonation in the posterior cerebral artery 
(PCA) over this prolonged cognitive stress (due to the small diameter of the PCA), we 
developed a protocol in which CBFv changes were measured in the middle cerebral artery 
(MCA). As a reduction in CBF may relate to hypocapnia in association with hyperventilation or 
increased tidal volume,(3),(4),(5) we included the measurement of respiratory rate and end 




 The results of our study of CBFv responses to orthostatic and prolonged cognitive 
stress in POTS and control groups are reported in Chapter 4. In this study, we demonstrated 
that prolonged cognitive stress was associated with a greater reduction in CBFv in the MCA in 
the patient group when compared with controls. We also studied the effect of midodrine, an 
alpha adrenergic agonist, on CBFv in the MCA in patients with POTS undergoing orthostatic 
and prolonged cognitive stress. Participants in this study were selected based on their 
previous symptomatic improvement in response to midodrine. We set out to determine if this 
symptomatic response was associated with an improvement in CBFv response to prolonged 
cognitive stress. The results of this study (reported in Chapter 5) were inconclusive. Whilst 
patients reported a significant improvement in symptom severity, and we detected an 
improvement in reaction time during cognitive testing following midodrine, we did not 
demonstrate an improvement in hemodynamic or CBFv responses to cognitive or orthostatic 
stress following administration of midodrine. This negative study could reflect a placebo effect 
in reporting of symptomatic improvement or that the study was underpowered to 
demonstrate  a difference in CBFv response, however it suggests that TCD measurement of 
CBFv in the MCA in response to orthostatic and prolonged cognitive stress may not be as 
useful as we had hoped as an objective marker of response for future therapeutic trials in 
patients with POTS. 
 
 In Chapter 6 we report on the use of plasma exchange therapy as a novel intervention 
in treatment resistant POTS.  The use of plasma exchange in POTS was based on positive 
repsonses to plasma exchange in patients with a related condition (autoimmune autonomic 
ganglionopathy) (6) as well as reports of auto-antibodies in the sera of patients with POTS. (7) 
Wells, 13 
 
The clinical course, cognitive and CBFv reponses to orthostatic and cognitive stress in a patient 
treated with acute and maintenance plasma exchange therapy are suggestive of some 
improvement with plasma exchange however the brief duration of response following each 
treatment and the lack of response in other patients did not support plasma exchange as a 
viable long term option for POTS.  
 
 
 Further studies are needed to evaluate TCD assessment of CBFv in POTS patients to 
define its utility in clinical practice. It would be of interest to study the CBFv response to 
prolonged cognitive stress after orthostatic stress in both POTS and control groups. A 
comparison of CBFv response to cognitive challenge measured by TCD with regional blood 
flow response using fMRI during an identical cognitive challenge would provide further insight 
into the utility of TCD as a tool to measure outcomes in clinical trials. As we advance our 
knowledge on the pathophysiology underlying this condition, a biomarker that correlates well 
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Chapter 1: Postural Tachycardia syndrome: current perspectives and 
literature review 
 











In addition to the published manuscript re-produced in this chapter (which provides an 
overview of POTS and its underlying pathophysiology), some additional detail is provided 
relevant to the contents of this thesis. Elaboration on the symptom of “brain fog” in POTS is 
followed by an overview of the use of TCD in the measurement of CBF dynamics and a 
description of the cognitive tools utilized in studies described in this thesis.  Finally, the 




 Postural tachycardia syndrome (POTS) is a chronic debilitating condition characterized by 
symptoms of lightheadedness, fatigue, palpitations, pre-syncope, sleep disturbances, cognitive 
impairment and brain fog in conjunction with an exaggerated increase in heart rate (HR) when 
upright, despite maintenance of a normal blood pressure. {Garland et al., 2015, #90822} The 
exaggerated HR response is defined as a sustained increment >30 beats per minute (bpm) in 
adults, or >40 bpm in children, that occurs within 10 minutes of standing or head up tilt test 
(HUTT). The nonspecific nature of symptoms, bell curve of HR responses to orthostasis in the 
general population and a lack of specific biomarkers have made it difficult to establish the true 
prevalence of POTS but estimates put it at approximately 170 cases per 100,000 individuals in 
the general population. (13) The onset of POTS symptoms may be gradual although symptoms 
may also appear abruptly following an immunological stimulus, such as vaccination or an 
infective illness. (14) Cohorts of patients with POTS in association with symptoms of 
Chapter 1: Current perspectives and literature review 
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concussion following a closed  
 
head injury have also been described. (15) There is a higher than expected prevalence of joint 
hypermobility, irritable bowel syndrome (IBS) and chronic fatigue syndrome (CFS) in patients 
with POTS. (16)  It is most commonly seen in adolescent and young adult females but can 
occur at all ages.  
 
 The pathophysiology underlying POTS may be multifactorial and vary in different 
subgroups. Autonomic dysfunction, dehydration, sympathetic tone, deconditioning, reduced 
venous return due to peripheral or splanchnic venous pooling may all contribute. (17)  
Autoimmunity and mast cell activation syndrome are thought to play a role in some patients with 
POTS. (7),(18),(19)    Multiple system dysfunction and  heterogeneity in presentation often lead 
to extensive investigation, with fragmented care provided by multiple specialists. In future, it 
may be possible to identify patients with genetic links, such as dysfunction of the 
noradrenaline transporter (NET), (20) which raises the possibility of targeted interventions 
such as the reactivation of NET. (21) However for the time being, therapies for this condition 
are limited and generally address intravascular volume, peripheral vascular tone or HR. Response 
to therapeutic interventions is variable and improvement in HR control does not always 
improve quality of life. (22),(23) Evidence base for POTS therapies is limited, with many options 
based on anecdotal evidence alone. (24)  
 
The association between POTS and several other clinical syndromes is described below, 
followed by a discussion of our current approach to clinical history, physical examination and  




targeted investigations to inform management. The potential to progress the evidence base 
for the clinical management of POTS is hampered by the heterogeneity of presentation and 
the lack of objectivity of symptom tools.   
 
Concurrent clinical syndromes  
 
 
Irritable Bowel Syndrome (IBS) 
 Symptoms of IBS, food intolerance and allergic sinusitis, are commonly reported in 
individuals with POTS. (13) Although rarely performed in clinical practice, studies utilizing 
plethysmography have demonstrated splanchnic venous pooling (consequent to localized 
small molecule related vasodilation) in patients with IBS. (25) An intact baroreflex response to 
the reduced venous return would explain the postural tachycardia seen in these patients. 
Nuclear medicine evidence of delayed gastric transit times may also reveal an autonomic 
neuropathy in some patients with concurrent IBS and POTS; however, an increased awareness 
of symptoms (hypervigilance) may be an important factor in others. (26) Serum tryptase taken 
immediately after an episode of flushing, or a 24-hour urinary N-methylhistamine level, may 
provide some evidence of mast cell activation; however, this is uncommon. (19) 
 
 Many patients go through a process of restricting their diet and/or food challenges for 
which standardized protocols may be used in an attempt to identify the triggers for symptoms 
of OI. (27) The benefit of a low fermentable oligo-, di- monosaccharides and polyoles diet is 
uncertain and a recent systematic review questioned the quality of evidence for this 
Chapter 1: Current perspectives and literature review 
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approach.(28) Interestingly, the treatment of POTS may improve IBS symptoms, as seen in a 
cohort of children treated with fludrocortisone. (29) 
 
Hypermobility Syndrome  
 Concurrent hypermobility, often referred to as Ehlers Danlos Syndrome, is 
overrepresented in patients with POTS. (30) The Beighton score is a standard tool used to 
document the presence of hypermobility. (31) Since hypermobility may reflect a connective 
tissue matrix weakness, a reduction in venous return due to poor vascular wall integrity, 
evident on ultrasound when the vessels collapse under gentle pressure from the ultrasound 
probe, can sometimes be observed. However, a higher prevalence of small fibre neuropathy in 
the hypermobile group and normal arterial stiffness (measured in large vessels using 
tonometry) suggest vessel wall integrity is not the only reason for concurrent joint 
hypermobility and POTS. (32) An association between anxiety, interoceptive sensibilities, 
chronic fatigue syndrome and either hypermobility or POTS has been reported by several 
groups. (33),(34),(35),(36) 
 
Vascular Compression syndrome  
 Vascular compression syndromes such as median arcuate ligament syndrome, thoracic 
outlet syndrome and pelvic compression syndrome have the potential to reduce venous return 
and hence trigger the baroreflex to precipitate postural tachycardia. (37),(38),(39) Turbulent 
flow or high peak systolic velocities in the superior mesenteric arteries may be identified 
during Doppler ultrasound, especially when provocative maneuvers such as standing (Figure 
1.1 A) and B), expiration or Valsalva increase the angle of the superior mesenteric arteries or 
celiac axis. (40),(41) Median arcuate ligament syndrome is an uncommon condition in which  




patients develop postprandial or post-exertional abdominal pain secondary to intermittent 
obstruction of celiac or superior mesenteric arteries by the median arcuate ligament, 
sometimes in association with celiac plexus compression (Figure 1.1C). (42) Thoracic outlet 
syndrome describes the association of symptoms provoked by muscle, fascial or bony 
compression of vascular structures or nerve fibres at the thoracic outlet. Vessel flow 
characteristics during provocative maneuvers, such as elevation or abduction of the forearm, 
can be documented during ultrasound assessment (Figure 1.1D), although the false-positive 
rate can be significant. (43) Increased cardiac sympathetic activity might also be generated by 
compression of the stellate ganglion or postganglionic efferent sympathetic fibres. (37) While 
the peripheral and splanchnic vessels are most commonly implicated as the sites of venous 
pooling in POTS, pelvic vein varicosities may also result in significant venous pooling and can 
potentially be identified using transabdominal or transvaginal pelvic duplex ultrasound. 
Embolization or sclerotherapy can sometimes provide symptomatic relief. (44) 
  





A               C 
 
 
Figure 1.1: Pulse Wave Doppler ultrasound in vascular compression syndrome 
 
Increase in Doppler intensity of the orange spectra and colour reversal due to aliasing (blue 
region in the centre of the vessel) indicates increase in blood flow velocity and turbulence in 
the compressed superior mesenteric artery of a patient upon change in posture from supine 
(A) to standing (B). In median arcuate ligament syndrome, the celiac artery may become 
compressed during expiration, resulting in increased blood flow velocity and turbulence, seen 
here as an increase in height during systole and broadening waveform during diastole (C). In 
thoracic outlet syndrome, the blood flow waveform is completely lost in the axillary artery 
upon arm raising (D). 
  





Clinical approach toward POTS diagnosis  
 
 The range of complex nonspecific symptoms experienced by patients with POTS can 
impede management. Careful history taking and clinical examination are essential but 
exhaustive investigations often add little value to the overall management of this condition.  
 
Clinical History  
 Individuals with POTS frequently present after a prolonged period of illness when OI 
may have developed as a result of deconditioning, disrupted circadian rhythm or dietary 
deficiencies. There is significant overlap in symptomatology between chronic fatigue 
syndrome (CFS), fibromyalgia, and POTS with no correlation between the severity of 
symptoms and the magnitude or consistency of postural tachycardia. Medical questionnaires 
can be useful in identifying relevant symptoms and past medical history sometimes lost in the 
plethora of symptoms offered by the patient. The circumstances surrounding symptom onset 
may suggest an autoimmune aetiology, with a traumatic or immunologic trigger. (14) Specific 
enquiry may also reveal concurrent conditions (Table 1.1) contributing to the severity of 
symptoms, including hypermobility, IBS or food intolerances, autonomic neuropathy and 
syncope. 




Table 1.1: Concurrent and exclusion diagnoses in patients with POTS and orthostatic 
intolerance 
 
Diagnosis Relevant history Relevant examination findings 
Concurrent diagnoses in 
patients with POTS 
  
Syncope Triggers and circumstances 
surrounding loss of 
consciousness episodes 
No specific examination findings 
Hypermobility Recurrent subluxation or 
dislocation of joints, bruising 
tendency 
Assessment of hyperextension at 
metacarpophalangeal joints, 
elbows, knees, hips and wrist 
flexion (Beighton score) 
Irritable bowel syndrome Frequent diarrhea, 
constipation and bloating 
Abdominal tenderness and 
bloating 
Autonomic neuropathy COMPASS 31 questionnaire 
useful for an overview of 
autonomic symptoms (Table 
1.2) 
Lack of HR variability with deep 
breathing and significant postural 
hypotension 
Postural hypotension Orthostatic symptoms often 
resolve when recumbent, 
careful medication history 
Lying and standing blood pressure 
with HR assessment 
Exclusion diagnoses for 
patients with OI 
  
Anemia or iron deficiency Blood loss (surgery, 
menorrhagia, melaena), 
reduced red meat 
consumption 
Pallor, pale conjunctivae 
Renal disease Nausea, vomiting, fatigue, loss 
of appetite 
Peripheral oedema, change in 
urinary pattern, treatment-
resistant hypertension 
Diabetes mellitus Polydipsia, polyuria, fatigue Ketotic breathe, unintentional 
weight loss 
Diabetes insipidus Polydipsia, polyuria Signs of dehydration 
Thyroid disease Abnormal HR when 
recumbent 
Resting tachycardia, eyelid 
retraction, goitre 
Adrenal insufficiency Prior steroid use Skin pigmentation 
Hypercorticolism Steroid use Striae, distribution of adipose 
tissue 
Malignancy Prior malignancy, weight loss, 
fatigue 
Lymphadenopathy, breast lumps, 
palpable mass on rectal 
examination 
Chronic infection Febrile illness at the onset of 
symptoms 
Fever 
Pulmonary embolism Chest pain, shortness of 
breath, recent immobility or 
previous deep vein thrombosis 
Pleural rub, supine tachycardia, 
lower limb swelling 
Arrythmias or cardiac disease Palpitations, symptoms not 
exclusively related to posture 
Abnormal pulse quality or rhythm, 
presence of cardiac murmurs 




 Specific enquiries on the use of supplements, current and previous medications can 
help identify the use of medications that may be exacerbating symptoms, either by reducing 
the intravascular volume (diuretics, mineralocorticoid receptor antagonists such as 
drosperidone), increasing vasodilation (calcium channel blockers, alpha-antagonists) or 
increasing fatigue (beta-receptor antagonists).  Salt and water intake, sleep hygiene, physical 
activity capability and symptoms of anxiety and depression are important to elicit. The 
presence of concentrated urine despite good oral fluid intake suggests insensible fluid and 
electrolyte loss and may reflect exacerbation secondary to activities such as hot yoga. The 
timing and number of hours spent sleeping may identify significant abnormalities in circadian 
rhythm or other sleep disorders. POTS may sometimes be accompanied by cholinergic 
symptoms (decreased saliva and tear production, delayed gastric transit associated with early 
satiety, nausea, constipation and bladder dysfunction) (45) or associated with symptoms and 
signs of autoimmune conditions. (46) Several validated questionnaires may be useful to 
explore the presence of autonomic features and track severity of symptoms in patients with 















Table 1.2: Adjunct Questionnaires 
 
 
Questionnaire Comments Pros Cons 
COMPASS 31 
(47) 




and orthostatic symptoms 
to reflect the extent of 
autonomic dysfunction 
Provides an overview of 
symptoms related to 
autonomic function in 
terms of frequency and 
evolution 
Presence of irritable 
bowel syndrome (which 
may not reflect 
autonomic dysfunction) 
can significantly affect 
the score 
Winker (48) Validated for occupational 
health assessments 
Evaluates the frequency 
of 10 orthostatic-related 
symptoms 
Does not provide a 






Validated in subjects with 
orthostatic hypotension and 
may be useful to evaluate 
acute changes during an 
orthostatic stress test 
Likert scale recording the 
severity of six orthostatic 
symptoms (and ability to 
stand and walk for short 
or long periods) 
Some uncertainties in 
scoring if symptoms ae 
severe but occur 
infrequently 
Short Form 36 
(SF -36) (50) 
Widely used, well-validated 
scale for quality of life 
assessments 
Contains 36 questions 
addressing social and 
functional domains 
reflecting the quality of 
life over the preceding 4 
weeks 
Some uncertainties in 
scoring if symptoms 
fluctuate or concurrent 
illness occurred during 
the 4 weeks 
Beighton score 
(31) 
One point for passive 
hyperextension of each 
elbow, each knee and each 
fifth metacarpophalangeal 
joint, as well as one point 
for hyperflexion of each 
wrist and one point for the 
ability to place the palms on 
the floor while standing 
with straight legs 
Useful score for joint 
hypermobility 
Does not discriminate 
between types of Ehlers 
Danlos Syndrome as 
there is no score for skin 











Clinical examination   
 
 HR and blood pressure (BP) should be assessed while the patient is supine and then 
during a 10-minute period of standing (Figure 1.2). If postural HR abnormalities are evident, 
tilt-table tests contribute little additional information. However, the timing and duration of the 
exaggerated HR response in patients with POTS has not been clearly defined, and the HR 
increment in an individual may demonstrate considerable daily variability. Therefore, if the 
patient reports typical postural symptoms but does not meet the criteria for POTS while 
standing in the clinic for 10 minutes, further investigation with tilt testing may still be 
warranted. (51) General physical examination may identify rashes, Raynaud’s phenomenon or 
acrocyanosis of dependent limbs as a result of venous pooling (Figure 1.3 A and B). Auscultation 
for carotid, renal and epigastric bruits and cardiac murmurs should be undertaken along with 
examination of joints for evidence of hypermobility (Figure 1.3 C), and examination of 
pupillary reactions to detect evidence of cholinergic failure (Holmes–Adie pupil). Table 1.1 
shows a list of conditions that may contribute to symptoms of OI in patients with POTS.   









Figure 1.2 Supine and upright HR and blood pressure. Supine and upright HR (orange) and blood 
pressure (blue) profiles of a normal subject (left panel) and a subject with POTS (right panel) 
demonstrating an exaggerated HR increase > 30 bpm) and relatively stable blood pressure. 
Abbreviations: bpm, beats per minute; HR, heart rate; POTS, postural tachycardia syndrome 
  









Figure 1.3. Common clinical signs. (A) Raynaud’s phenomenon; (B) acrocyanosis; (C) 
hypermobility demonstrating the ability to bring the thumb in contact with the ipsilateral 
forearm as part of the Beighton score (for more information on Beighton scoring system, see 
Table 1.2). In (B), the right leg had been dependent whilst the left leg had remained on the 
bed for a few minutes revealing the colour change seen with venous pooling. Images were 
kindly provided by patients along with their written informed consent to publish the images 
  






Cardiovascular investigations  
 An electrocardiogram and 24-hour monitoring of cardiac rhythm may identify 
conduction abnormalities or unexpected arrhythmias on rare occasions. More commonly, 
sinus tachycardia is seen to correlate with symptoms of OI. 
 
Tilt-table test  
 The head-up tilt-table test (HUTT) is the gold standard for diagnosis of orthostatic 
cardiovascular dysregulation and vasovagal syncope.  HUTT increases the sensitivity to detect 
postural tachycardia as the calf muscles that contribute to venous return when standing are not 
engaged when the patient is supported on a tilt table. Some centers adopt a provocation 
protocol using either sublingual nitrates or intravenous infusion of isoproterenol. (52)  
Syncope can be induced in individuals without POTS or orthostatic dysregulation with sufficient 
provocation, however, and we do not recommend this approach. (53) While positive response 
to acute intervention with intravenous fluids and midodrine has been demonstrated during a 
5-minute tilt test, this has yet to be correlated with long-term response. (54) 
 
Autonomic Testing 
 Baroreceptors are stretch-sensitive mechanoreceptors located in the aortic arch and 
carotid sinuses. Changes in blood pressure alter the stretch of these mechanoreceptors, 
resulting in a rapid change in intensity of impulses in the autonomic nerve fibres projecting to 
centres in the brain. This in turn alters the intensity of impulses in the nerve fibres projecting 
from the autonomic centres of the brain to the sinus node, resulting in a rapid change in HR.  




Elevated BP activates the baroreflex, leading to decreases in HR and BP.  A drop in BP will 
inhibit the baroreflex, leading to increases in HR and BP. Baroreflex-induced changes in BP are 
mediated by both branches of the autonomic nervous system: the parasympathetic and 
sympathetic systems. Rapid baroreflex adjustments are critical for regulation of HR and 
peripheral vascular resistance during orthostatic stress. (55),(56) In individuals with reduced 
venous return during orthostasis but an intact baroreflex, persistent reduction in stretch of 
the baroreceptors results in an exaggerated and sustained tachycardia. During deep 
inspiration and expiration while supine, however, individuals with POTS generally have a normal 
variation in HR variability (preserved vagal function) as the baroreflex responds to changes in 
intrathoracic pressure. Immediately following a Valsalva maneuver, however, the normal 
rebound in blood pressure (phase IV) is exaggerated, reflecting a vigorous pressor response. 
A reduced ability to buffer a fall in activation (stretch) of the baroreceptors may occur in a 
subgroup of “hyperadrenergic” POTS patients with high background sympathetic tone.  
 
Plasma and urine catecholamines 
 Hyperadrenergic POTS may relate to an increase in production of norepinephrine (57) 
or defective norepinephrine clearance. (58),(59),(60),(61),(62) The increment in 
norepinephrine after 10 minutes of head-up tilt versus supine rest has been used to 
dichotomize individuals with POTS into those with normal and those with hyperadrenergic 
responses. (63) Theoretically, patients with higher norepinephrine levels during HUTT are less 
likely to respond to alpha-agonist therapy (e.g., midodrine). One small study has shown patients 
with neuropathic POTS had a better HR response to midodrine when compared with patients 
with hyperadrenergic POTS, however symptomatic response was not evaluated. (64) A search  




for single-nucleotide polymorphisms in the SLC6A2 gene encoding the norepinephrine 
transporter (NET) failed to demonstrate pathogenic variants in patients with POTS, (65) but the 
expression of NET on the cell membrane is dependent on phosphorylation and glycosylation, 
indicating that other genes or epigenetic modification may contribute to hyperadrenergic 
POTS. (66) Further, sympathetic denervation in neuropathic POTS could be expected to result 
in a decreased myocardial uptake of meta-iodobenzylguanidine, a noradrenaline analog readily 
taken up by sympathetic nerves via NET. (67) However, there was no correlation between 
cardiac meta-iodobenzylguanidine uptake and sympathetic skin responses, catecholamine 
levels, symptom severity or other autonomic parameters in POTS patients. (68) Measurement 
of norepinephrine and its metabolites are predominantly of interest as a research tool and are 
rarely performed in clinical practice to manage POTS. 
 
Assessment of intravascular volume 
 Theoretically, low angiotensin levels may exacerbate POTS, as angiotensin has both a 
direct vasoconstrictor effect and drives renal fluid and sodium reuptake by stimulating 
aldosterone release from the adrenals. Lower than expected levels of renin and angiotensin 
were demonstrated in a group of patients with POTS, despite lower blood volume measures 
than the control group, although the implications of this finding for treatment are unclear. (69) 
Fludrocortisone, a synthetic aldosterone analog, is often used empirically to address the 
potential contribution of hypovolemia to orthostatic symptoms. In pediatric POTS patients 
with urinary sodium excretion <124 mmol/L per 24 hours, pretreatment symptom burden was 
significantly higher while posttreatment response to oral rehydration salts was significantly 
greater. (70) In practice, the assessment of intravascular volume, and integrity of the renin– 




angiotensin system, are rarely performed, with techniques to measure total blood volume 
(carbon monoxide rebreathing, thermodilution, dye dilution, Technetium-99m or Chromium-
51 labeled erythrocytes and Iodine-131 labeled albumin) typically reserved for research 
purposes only. (71),(72),(73) 
 
 Evidence of venous pooling can be demonstrated using labeled erythrocytes in 
conjunction with a gamma counter, impedance plethysmography and strain gauge measures 
of calf diameter increment during venous occlusion and head- up tilt. (74),(75),(76) Usually, 
individuals with POTS without excessive peripheral pooling have either hypovolemia (as 
demonstrated by indocyanine green dye dilution) or increased splanchnic blood flow despite 
peripheral vasoconstriction. (76) Using Doppler ultrasound, an increase in superior mesenteric 
artery blood flow can be demonstrated in some patients with POTS. (77) At present, the above 
tools are used primarily in research studies rather than to guide or assess response to therapy. 
 
Immunologic workup 
 There is uncertainty around the significance of autoantibodies in POTS. (78) Sera from 
patients with POTS have produced exaggerated vascular constriction of a rat arteriole in vitro 
and an immunofluorescent assay identified autoantibodies binding to adrenergic receptors. 
(7)  However, these tests are confined to research use and not used in current clinical practice. 
Autoantibodies targeting the components of nicotinic receptors are generally associated with 
orthostatic hypotension rather than tachycardia, but low levels of these, and many other  
 




autoantibodies, have been detected in patients with POTS. (45),(79) At present, 
immunotherapy for POTS patients has been understudied and, in general, the risks are 
considered to outweigh the uncertain benefits. In contrast, immunotherapy has been successful 
in the treatment of generalized autonomic dysfunction associated with cholinergic 
autoantibodies such as in ganglionopathy. (80) Skin prick testing is sometimes undertaken to 
identify potential triggers to IgE-mediated mast cell histamine release. Urinary 
methylhistamine or serum tryptase levels performed on specimens taken during an episode of 
flushing and tachycardia may also provide some evidence of mast cell involvement. However, 
false-positive and -negative results may occur and ultimately, responses to food elimination 
diets and food challenges may provide the most clinically relevant information. 
 
Brain Fog and Cerebral Blood Flow 
 Brain fog, most commonly described as “forgetful”, “difficulty thinking”, “difficulty 
focusing”, “cloudy” and “difficulty finding the right words or communicating” is a common 
symptom in POTS. (81) To determine the contribution of CBF dynamics to patient symptoms, 
Doppler ultrasound has been used to measure CBFv during postural maneuvers and cognitive 
tasks. (82),(83) Inability to buffer the cerebral circulation against peripheral circulation 
changes during orthostasis and excessive cerebral vascular constriction may be present, 
although these findings can be variable. (84),(85) An increased oscillatory pattern of CBF has 
been described in patients with POTS during head-up tilt that has been demonstrated to be 
associated with marked reduction in cognitive performance and functional hyperemia. 
(86),(82) Further, downregulation of nitric oxide receptor sites may explain the impaired nitric 
oxide-related cerebral vasodilation and blunted CBFv following administration of sodium  




nitroprusside while supine and during upright tilt. (87)  
 
 End tidal carbon dioxide (ETCO2) is often used as a marker for the presence of 
hypocapnia, a cause of cerebral vasoconstriction which may contribute to cerebral 
hypoperfusion. (4),(88) A decrease in ETCO2 of 1mmHg decreases CBF by 3%. (4),(89) 
Hypocapnia may be the result of an increase in respiratory rate (hyperventilation) or an 
increase in tidal volume (hyperpnoea). (89) An increase in tidal volume has been 
demonstrated in a group of patients with POTS in whom the primary symptom was shortness 
of breath,(3) whilst hyperventilation was documented in a group of patients with POTS in 
whom excessive thoracic venous pooling during orthostasis was associated with an increase 
in sympathetic tone. (5)  
 
Transcranial Doppler Ultrasound 
 
 The anatomy of the middle cerebral artery (MCA) is ideal for Transcranial doppler 
ultrasound (TCD) measurement of CBFv. The direction of blood flow is towards the temporal 
window (thinner area of bone above the zygomatic arch) through which the ultrasound beam 
can pass. The angle of the ultrasound beam relative to the flow through the vessel is termed 
the angle of insonance. To optimize the signal, this angle should be as close as possible to the 
direction of flow in the vessel and be maintained as stably as possible. In the MCA this is 
usually achievable with the signal identifiable over a range of depths (40-55 mm) in most 
individuals. CBF results obtained from TCD assessment of CBFv in MCA correlate well with gold 
standard methodology for quantifying CBF. (90)  




 Transcranial doppler ultrasound (TCD) provides an output of mean CBFv, taking into 
account the range of velocities (due to the laminar flow) in the vessel. (91)  Outcome measures 
obtained from duplex ultrasound of the CBFv waveform include mean velocity (MV) often 
expressed as time averaged peak (TAP), peak systolic velocity (PSV), end diastolic velocity 
(EDV), as well as calculated indices of resistance index (RI) and pulsatility index (PI), where PI 
= (PSV – EDV) / MV. (92) PI is high when cerebral vasoconstriction or high intracranial pressure 
results in decreased diastolic flow. 
  
 Non-duplex TCD is a convenient, non-invasive technique that allows for real time 
recording of the CBFv waveform. Duplex, or Transcranial color-coded duplex ultrasonography 
(TCDD) provides the capability to directly visualise the insonated artery. (93) The imaging 
modality can be helpful in locating the posterior cerebral artery (PCA), a smaller diameter 
vessel with direction of flow at an obtuse angle relative to an ultrasound beam directed 
through the temporal window. Near infrared spectroscopy may provide an alternative to TCD 
CBFv in studies of cerebral hypoperfusion but is less sensitive to regional CBF changes when 
compared with TCD. (94) 
 
 Usually, dynamic autoregulation ensures CBF is maintained despite spontaneous 
changes in BP secondary to standing, exercising or respiratory related alterations in venous 
return to the heart. (95) Symptoms of hypoperfusion become noticeable when CBFv is 
reduced by 50%. (96) Since BP is, by definition, maintained in patients with POTS,(97) and 
POTS children and young adults have previously been found to have intact autoregulation,(98) 
the cognitive difficulties encountered by patients with POTS may relate to impaired  




neurovascular coupling (NVC). NVC is the increase in regional CBF in response to increased 




 A standardised cognitive stress, in association with measures of CBF, allows for 
simultaneous assessment of neurovascular coupling and cognitive performance. Cambridge 
Neuropsychological Test Automated Battery, (CANTAB) (Cambridge Cognition Ltd., 
Cambridge, UK) is an ipad based neurocognitive assessment program in which tasks are 
accompanied by recorded instruction scripts, reducing the potential for unconscious bias 
introduced by individuals administering the neurocognitive tasks. (101) Others have reported 
good test / re-test reliability with CANTAB tasks. (102) CANTAB includes tasks designed to 
assess function in different cognitive domains including attention and psychomotor speed, 
memory, and executive function (Table 1.3). Multiple output variables are recorded for all 
tasks.  
Table 1.3: CANTAB cognitive domain tasks  
 




Attention and psychomotor 
speed 
RTI: reaction time 
RVIP: correct responses 
DMS Memory DMS: correct responses for 
trials with 12 second delay 
MTT (AST) Executive function MTT: correct responses 
 
RTI: reaction time index, RVIP: rapid visual information processing, DMS: delayed matching to 
sample, PAL: paired associates learning, SWM: spatial working memory, MTT: multi-task 
(previously referred to as AST: Attention switching task) 




 Reaction time index (RTI) and Rapid visual information processing (RVIP) provide 
multiple trials within each task, increasing the potential to capture subtle changes in cognitive  
ability in the domain of attention and psychomotor speed. A pre-recorded script for the 
Reaction time index (RTI) task directs the participant to release a button and tap a target when 
it appears on an ipad screen. This simple task allows participants to become familiar with 
listening to recorded instructions and to respond by touching the ipad screen whilst assessing 
motor response time. The Rapid visual information processing (RVIP) task is more challenging  
and requires sustained attention. During this task digits appear on the screen (at a rate of 100 
digits per minute) and participants are directed to press a button whenever they identify any 
of the three target sequences (2-4-6, 3-5-7, or 4-6-8). The brief time between appearance of 
digits minimises the risk of conscious or unconscious manipulation of results. The high number  
of target sequences to identify provides the opportunity to discriminate between relatively 
subtle levels of cognitive dysfunction. (103)   
 
 In the Delayed Match to Sample (DMS) task, participants are shown a complex 
multicoloured, geometric object. A training phase of the task keeps the target object in view 
while the participant identifies the matching object from 4 options provided below the target 
object. In the assessed trials, the target object disappears for 4, 8 or 12 seconds before the 
response options appear. The multitasking test (previously referred to as the attention 
switching task (AST) provides an assessment of executive function. In this task participants 
touch “left” or “right” buttons in response to a single word question, “direction” or “side” 
appearing at the top of the screen. The target image to which the question refers is an arrow 
that appears in different orientations and positions on the screen.  






Approach to therapy for patients with POTS 
 
 The first consideration in managing POTS is patient education concerning 
pathophysiology and symptoms, with numerous simple lifestyle strategies aimed to reduce the 
burden of POTS-related symptoms. Table 1.4 provides a summary of the approach to treating 
POTS patients based on their dominant symptoms. 
 
Table 1.4: Choice of therapy based on phenotype 
Symptoms or signs Rationale Therapy 
All patients Avoidance of external 
factors contributing to 
orthostatic-related 
symptoms 
Avoid overheating, elevate 
head of bed, lifestyle 
management including diet, 
sleep hygiene and a 
recumbent exercise 
program(104) 
Use of physical counter 
maneuvers and tonic muscle 
contraction to combat pre-
syncopal symptoms 
White/cold peripheries and 
narrow upright pulse 
pressure (systolic-diastolic 
BP)  
Suggestive of low blood 
volume 
Increase oral salt and water 
intake and consider adding 
fludrocortisone 
Acrocyanosis of dependent 
peripheries 
Possible venous pooling Use of compression 
garments when upright(74) 
and consider adding 
vasopressor therapy (e.g., 
midodrine) 




Confirm normal thyroid 
function tests, anxiety 
management, rate control 
with low dose beta2 
antagonists (propranolol) or 
ivabradine 
Concurrent IBS Splanchnic pooling Consider referral to a 
dietician and/or trial of an 
elimination diet 






 Receiving an explanation for the physiologic basis underlying POTS can be very 
reassuring for patients. Furthermore, strategies to avoid triggers and manage symptoms are 
more likely to be adopted if patients understand the underlying rationale. Nonpharmacologic 
strategies include avoidance of exposures that may contribute to overheating, improving 
venous return by activation of calf muscles and tonic muscle contraction when lightheaded. 
Maintaining good hydration may include supplementing salt and water intake and withdrawal 
of medications that interfere with fluid balance (drospirenone, diuretics). Where food 
intolerances are problematic with suspected splanchnic pooling, providing dietary advice and 
referral to a dietician may be of benefit. The use of full-length pressure stockings can be of 
considerable benefit in reducing POTS symptoms. Previously, it has been demonstrated that a 
45–50 mmHg inflatable pressure suit significantly reduced abnormal HR and blood pressure 
responses when patients with orthostatic intolerance were upright. (74) However, difficulty in 
applying compression garments and reduced user compliance during warmer weather (when 
they are likely to be of greatest benefit) limit the translation of potential benefits from 
external compression into significant benefit in many patients. 
 
 In patients with autonomic failure, sleeping in a seated position can reduce loss of salt 
and water at night. (105) It has been postulated that increased renin secretion and consequent 
aldosterone increase can occur with reduced renal arterial pressure when a patient lies with 
the head of the bed raised by ~10 cm. Further, a graduated exercise program incorporating 
recumbent exercises may also be beneficial in POTS. (104)  Short-term exercise training has  




been shown   to increase the baroreflex sensitivity in POTS patients and decrease the upright  
HR. (106) It is important to keep a modest expectation of activity levels in the early phase to 
avoid post-exertional fatigue and abandonment of the program, as a gradual increase in 
exercise can result in significant improvement in both symptoms and orthostatic HR in patients 
with POTS. (104),(107),(108) Other lifestyle factors include adoption of good sleep hygiene to 
address disrupted circadian rhythm, and psychologic support, to encourage realistic 
expectations of integration back into the study or workplace. 
 
Pharmacological interventions 
 A recent consensus statement has highlighted a lack of quality evidence for the use of 
pharmacotherapy in POTS. (109) Empirical trials of medications are generally adopted based 
on the clinician’s impression of the POTS phenotype (Table 1.3). In practice, single or 
combination therapies directed at increasing intravascular volume, increasing peripheral 
vasoconstriction and controlling HR are often employed. Fludrocortisone is a reasonable option 
for increasing the intravascular volume, while midodrine is useful in those with peripheral 
pooling. 
 
 Specifically, midodrine was superior to placebo in the subgroup of patients with 
peripheral venous pooling (as indicated by an increase in calf diameter during venous occlusion 
or tilt), whereas in patients without peripheral pooling, the HR change with midodrine was not 
significantly different from placebo. (64) Nonselective beta2 antagonists such as low-dose 
propranolol may be effective for treating the elevated HR. (110) These are preferred over the 
cardio-selective ones, given the added potential for reducing pathogenic peripheral or  




splanchnic vasodilation. One major limiting factor in the use of a beta2-receptor antagonist is 
the potential for worsening chronic fatigue symptoms that are often present in POTS patients.  
Ivabradine is an alternative rate control agent with some benefit in POTS. (111) Rescue therapy 
with intravenous saline during acute decompensation can be helpful, and intermittent infusions 




 Several other POTS interventions have been reported in case series. In specialized 
centers, patients with significant postprandial tachycardia are occasionally treated with 
octreotide, a somatostatin analog, used to reduce splanchnic pooling. (113),(114) However, the 
need for subcutaneous or intramuscular administration, as well as the cost and side effect 
profile of octreotide have limited its use. A small case series on sinus node modification has 
found no significant benefits. (115) There is minimal information on the effect of 
immunomodulatory therapies, despite data suggesting a correlation between immune 
dysregulation and POTS. (116) Good response to intravenous immunoglobulin has been 
described in two patients with POTS in association with antiphospholipid syndrome. (117) 
Several miscellaneous therapies have been reported in POTS patients, but these remain 
investigational: erythropoietin, modafinil, methylphenidate and pyridostigmine. 
(118),(119),(120),(121) The predominance of POTS in young females could reflect an 
interaction between female hormones and mineralocorticoid receptors; however, the effect of 
manipulating female hormones requires further study. Oral contraceptives containing 
drosperinone are theoretically best avoided, given they are antagonists at the  




mineralocorticoid receptors. (122) A trial of histamine antagonists may also be considered 





 While there is no evidence for increased mortality associated with POTS, significant 
morbidities may persist. The prognosis of this condition is difficult to ascertain due to the 
heterogeneity and our incomplete understanding of the underlying pathology. Nevertheless, 
insights on the prognosis can be gained from the reports from several centers. A prospective, 
longitudinal study of 56 patients who were treated at the Mayo clinic with a combination of 
nonpharmacologic interventions and beta-blockers (54%), fludrocortisone (24%) or midodrine 
(17%) found improvement in 70% of patients, while 30% became worse after 1 year of 
treatment. (123) A retrospective review of POTS patients from the same clinic showed 
symptomatic improvement in up to 80%, although only 33% were managing recreational 
activities 5 years after diagnosis and 73% were still requiring treatments. (124) Questionnaires 
returned by 172 of 502 patients from another retrospective study indicated symptom 
resolution in 19%, improvement in 51% and unchanged or worsened symptoms in 12% of POTS 
patients at 5 years. (125) Thirty-one percent of patients responding to a phone questionnaire 
reported being asymptomatic ~10 years after their first consult. (126) Taken together, the 
majority of POTS patients may experience improvements in their symptom severity, while 
symptom progression and complete recovery are evident only in a minority. 
 




Future prospects – immunotherapy 
 
 It has been known for decades that the autonomic and immune systems are intimately 
connected. The “inflammatory reflex” or “cholinergic anti-inflammatory pathway”(127) is  
triggered by inflammatory cytokines released in response to an infection or inflammation 
binding to receptors on afferent vagal fibres. Connections in the midbrain result in down- 
regulation of sympathetic outflow, activation of the hypothalamic-pituitary axis and activation 
of the vagal dorsal motor nucleus in the medulla from which efferent vagal fibres carry the 
signal throughout the body, resulting in the production of anti-inflammatory cytokines. (128) 
Since vagal tone is also controlled through baroreceptor stimulation, and sympathetic activity 
is modified by anxiety and physical activity, it is not surprising that autonomic function is 
altered in patients with immune dysregulation and patients with autonomic dysfunction may 
have altered immune regulation.   
 
 Invitro experiments have demonstrated that sera and IgG fractions from patients with 
POTS affect animal arterioles and heart myocytes, altering constriction and rate of contraction 
respectively through interaction with adrenergic, muscarinic and/or nicotinic 
receptors.(7),(129) Through comparison of control and patient IgG and confirmation with 
mass spectroscopy and immunoblot against commercial antibodies, Wang et al were able to 
demonstrate the sera from patients with POTS contained 70 unique autoantibodies against 
proteins in cardiac lipid rafts. (79) (Lipid rafts are platforms within plasma membranes 
important in the integration of signal transduction.) The antibodies bound proteins specific to 
multiple cell functions including energy and adrenergic pathways. Thus, it appears that 
multiple autoantibodies may contribute to the clinical syndrome of excessive tachycardia in  
 




response to orthostatic challenge in at least a subset of patients with POTS.  
 
 The risk of many immunotherapies outweighs the potential for benefit in a non-lethal 
condition such as POTS. Plasmapheresis has a low risk profile, however, and is used routinely 
in the collection of immunoglobulin from healthy donors, often on a weekly basis. (130) During  
plasmapheresis, cells are separated from plasma and returned to the patient. The plasma is 
either filtered, extracting antibodies before returning to the patient, or it can be discarded 
and the patient is given fluid replacement, usually with 4% albumin (plasma exchange). 
Plasmapheresis is used for acute treatment of a number of conditions in which autoantibodies 
are pathogenic (Guillain Barre Syndrome, Myasthenia Gravis, Chronic Idiopathic 
Demyelinating Polyneuropathy), primarily to treat a patient during an acute flare of disease, 
since it does not prevent further antibody production.  
 
 Reports of the use of plasmapheresis as a therapy in patients with orthostatic 
intolerance are limited. A case series of 6 patients with a phenotype of autoimmune 
autonomic ganglionopathy (AAG) noted improvement following immunotherapy tailored to 
the individual response (intravenous immunoglobulin, progressing to plasmapheresis +/-
mycophenolate mofetil). (80) In a series of 3 patients with AAG, treatment with 
plasmapheresis was followed by an improvement in cognitive function but no change in 
hemodynamics whilst seated. (131) 
 
 The effect of plasmapheresis in patients with POTS is unknown. If autoantibodies are 
driving orthostatic tachycardia, however, removal of these autoantibodies by plasma  




exchange may reduce morbidity in POTS patients resistant to other therapies. Plasma 
exchange places a significant burden on limited medical resources, however. Thus, validation 
of objective measures of response to the use of plasma exchange is vital. Since HR control has 
not correlated with symptom severity in previous studies of POTS, objective measures of 
cognitive function and CBF are potential parameters to guide treatment selection and assess 




 The mechanisms underlying POTS are complex and remain poorly understood. The 
diagnosis is based on clinical history and determination of BP and HR responses in the upright 
posture. Targeted investigations focusing on autonomic function, assessment of intravascular 
volume, genetic and immunologic workup may help to identify factors contributing to the 
symptom complex in a subset of patients. Currently, therapies for this condition focus on 
symptom control but in future the potential for therapies targeting genetic or immunological 
anomalies may be considered. Further research is needed to help clarify the optimal approach 
to diagnosis, evaluate novel therapeutics, and inform long-term prognosis of this debilitating 
condition. The subjective nature of symptom questionnaires and the limitations in cognitive 
assessment tools to detect small changes in cognitive function call for more objective 
physiologic measurements that can be used to guide clinical management of this debilitating 
condition. 
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Chapter 2: Efficacy of Therapies for Postural Tachycardia Syndrome: A 
Systematic Review and Meta-analysis  
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In this chapter, the paucity of evidence for therapeutic interventions currently considered 
standard of care is detailed. One of the major difficulties in performing randomised controlled 
trials in POTS is the lack of objective outcome measures. Symptom scores are therefore the 
usual measure of “efficacy” in these studies and thus the tools utilised to assess symptom 
scores are discussed. Detail on the level of symptom score considered to represent efficacy is 
often missing, however.   Key areas for future research in this condition is therefore the 
standardisation of symptom assessment and the correlation of symptom score with an 
objective biological marker.   
 
Abstract 
Objective: To identify the evidence base and evaluate the efficacy of each treatment for 
postural tachycardia syndrome (POTS) in light of a recent consensus statement highlighting 
the lack of treatment options with clear benefit to risk ratio for this debilitating condition.  
Patients and Methods: The CENTRAL (Cochrane Central Register of Controlled Trials), Pubmed 
and EMBASE databases from inception to May 2017 were searched using the terms “postural” 
AND “tachycardia” AND “syndrome”. A total of 135 full-text publications were screened after 
excluding duplicates (n=681), conference abstracts (n=467) and records that did not relate to 
POTS therapy (n=876). We included 28 studies with at least 4 POTS patients in which 
symptomatic response was reported after more than 4 weeks of therapy. This review was 
performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) statement. Two investigators independently performed the data extraction 
and evaluated the quality of evidence. 
Results: This study comprised a total of 25 case series and 3 small randomized controlled trials 
that evaluated 755 and 103 patients with POTS, respectively. Interventions directed at 
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increasing intravascular volume, increasing peripheral or splanchnic vascular tone, controlling 
heart rate and increasing exercise tolerance demonstrate moderate efficacy (range 51-72%). 
Few data exist on their comparative effectiveness. Significant heterogeneities were seen in 
terms of patient age, symptom severity, and the measures used to evaluate treatment 
efficacy.  
Conclusion: The current evidence base to guide optimal management of patients with POTS 
is extremely limited. More high-quality collaborative research with standardized reporting of 





 Postural tachycardia syndrome (POTS) is a chronic debilitating condition that can 
substantially affect quality of life (QOL), cognition and psychosocial well-being. 
(8),(26),(132),(133) Its prevalence has been estimated to be 170 cases per 100,000 individuals. 
(134) The hallmark of POTS is a sustained heart rate increment of more than 30 beats per 
minute (bpm) in adults (>40 bpm in children aged 12-19 years) during the first 10 minutes of 
head up tilt (or upright posture) in association with symptoms of orthostatic intolerance (e.g. 
pre-syncope, brain fog) and in the absence of orthostatic hypotension. (97),(135) Usually, the 
symptoms of POTS develop in childhood or early adult life and is seen predominantly in 
females. (97) Patients with POTS commonly report symptoms of palpitations, dizziness and 
visual disturbances that often improve when recumbent. Symptoms of fatigue and difficulties 
with cognition are often less responsive to postural manoeuvres. Two main subtypes of POTS 
have been described, with neuropathic POTS involving reduced noradrenergic 
vasoconstriction in the extremities or the splanchnic vasculature, and hyperadrenergic POTS  
 




involving excessive noradrenergic vasoconstriction, reduced calf blood flow, and prominent 
symptoms of sympathetic activation. (64),(132),(134) 
 
 Recently, the Heart Rhythm Society released an expert consensus statement on the 
diagnosis and treatment of POTS. (109) Strikingly, there was a lack of randomized controlled 
trial (RCT) data on POTS treatment, with most recommendations derived from consensus 
opinions or weaker studies. Furthermore, there was a distinct lack of management strategies 
with clear benefit to risk ratios for this condition (Class IIa or higher according to the American 
College of Cardiology Foundation/American Heart Association Taskforce on practice 
guidelines). We therefore undertook a thorough systematic review and meta-analysis of the 
literature to clarify the current evidence base surrounding the treatment of POTS and evaluate 




 A search of the CENTRAL (Cochrane Central Register of Controlled Trials), PubMed and 
EMBASE databases from inception to May 2017 using the terms “postural” AND “tachycardia” 
AND “syndrome” extracted 2,141 records (Figure 2.1). A further 18 records were identified 
from references of review articles. We then excluded duplicates (n=681), conference abstracts 
(n=467) and records that did not relate to treatment of POTS (n=876). The full text of the 
remaining 135 articles was reviewed to identify original data regarding a symptomatic 
response to any specific therapy over at least 4 weeks.  
 
 








 The Heyland Methodological Quality Score was used to rate the quality of the RCTs. 
The score does not take into account the power of the study to identify a true difference 
between groups, but it does take into account patient selection, degree of blinding to 
intervention, whether groups were equal at baseline, whether co-interventions were 
adequately described and equal across groups, whether objective definitions of outcome 
measurements were used, and whether all patients were properly accounted for in the 
analysis (intention-to-treat). Case series were given a rating of 4 using the quality rating 
scheme modified from Oxford Centre for Evidence-Based Medicine. Each of the included 
studies was assessed independently by 2 investigators (RW and DHL). Discordant assessments 
were resolved by discussion. For each study, the following data elements were extracted: 
patient number, mean age and percentage of females in the study, study design, intervention  
 
 




(including dose, mode and frequency of administration), duration of follow-up, symptomatic 
efficacy and the tool used to measure symptomatic response. Treatment efficacy was often  
reported after excluding patients discontinuing therapy or lost to follow-up. We therefore 
extracted the number of individuals in all arms of each study and, where available, the number 
of individuals excluded from the intention-to-treat cohort during efficacy calculations.  
 
 We performed a meta-analysis of individual study data showing treatment efficacy 
when there were at least 2 studies evaluating the same therapy. Efficacy, defined as 
proportion of the responders in each study cohort, was transformed using the Freeman-Tukey 
arcsine transformation and was pooled across studies using the DerSimonian-Laird random 
effects method. Pooled estimates and their 95% CIs were back-transformed to give summary 
percentages for each treatment. Statistical heterogeneity was assessed using the I2 statistic.  
 
Publication bias was assessed by visual inspection of funnel plots and statistical assessment of 
asymmetry based on a weighted linear regression of treatment effect on standard error where 






 Of the 135 full text publications reviewed, 70 were excluded as no new treatment data 
was reported (Figure 2.1). Thirty-seven publications were further excluded for the following 
reasons: 8 reports involved 3 or fewer patients; 6 did not relate outcomes to a specific  




intervention, and 23 involved single-day interventions without longer-term follow-up data. 
Thus, the final analysis included 28 publications reporting symptomatic outcomes after 
treatment of 858 patients with POTS. Both pediatric and adult patients were included because 
onset of POTS is common from childhood to early adult life. 
 
Intravascular volume expansion 
 There were 5 publications involving 160 patients treated with strategies directed 
toward increasing intravascular volume (Table 1). (23),(29),(112),(136),(137) The efficacy for 
intravascular volume expansion reported in these publications ranged from 53% to 93%. 
Notably, patient populations were heterogeneous, with predominantly treatment-naïve 
pediatric patients with mild symptoms in the studies of oral supplements and predominantly 
treatment-resistant adult patients in the studies of intravenous (IV) fluid supplementation. 
Only 1 of these studies included randomization to alternate treatment strategies. This RCT 
consisted of a control arm of 15 children (aged 6-17 years) given advice to increase salt and 
water intake. Children in the other 2 arms of the study were given either midodrine or beta-
receptor blockers. (23) The remainder of the intravascular volume publications are case series 
describing outcomes after oral rehydration solution, intermittent IV fluid infusion, or oral  
fludrocortisone. Ruzieh et al. (112) describe a 93% efficacy with long-term IV fluid 
administration in treatment-resistant patients. The publication by Fortunato (29) involved a 
small group of children with POTS presenting with gastrointestinal symptoms. (29) 
Assessment of efficacy in this study was based on the individual symptoms that improved 
(nausea, dizziness, abdominal pain, flushing, and missing school improved, but scores for 
vomiting, syncope, constipation, and anorexia did not) rather than on the number of patients  




responding. A commonly cited publication including patients with orthostatic intolerance was 
not included because it is unclear whether these patients had POTS. We did not find 
publications matching the search criteria that related to the use of desmopressin.  
 
Legend Table 2.1: Intravascular volume expansion & Vasopressor 
 
abid = twice daily; CNHSQ = Children’s National Health System Questionnaire (25 questions 
assessing quality of life); IM = intramuscular; LAR = long acting release, NA= not available; 
OHQ = Orthostatic Hypotension Questionnaire; RCT = randomized controlled trial; SC = 
subcutaneous; SQ (28) = 28 symptom questionnaire; WFDI = Walker Functional Disability 
Inventory; WSS = Winker symptom score; tid = three times daily;  
bHeyland Methodological Quality Score of 8 or greater denotes high quality; all other studies 
graded 4 using the rating scheme modified from the Oxford Centre for Evidence-Based 
Medicine represent case-series or case-controlled studies;   
cIncludes patients with orthostatic hypotension;  
dUnclear if 79% of patients improved or if mean improvement in symptoms across the whole 
cohort (including patients with hypotension) was 79%;  
eIncludes patients with syncope;  
fResults reported by symptom, not by patient;  
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Table 2.1: Intravascular volume expansion & Vasopressor 









 Six studies reported on the symptomatic outcomes following vasopressor therapy 
(Table 2.1). The vasopressor agents included midodrine (3 publications, 76 
children),(23),(138),(139) droxidopa (1  publication, 37 patients),(140) and octreotide (2 
publications, 9 patients). (113),(141) Midodrine was superior to conventional therapy (salt 
supplementation) in the nonblinded RCT involving pediatric patients, despite the very low 
dose being used. (23) The data from Lai et al (138) relate to a postal survey in which 
adolescents were asked which medications had improved their symptoms.  
 
 The pooled efficacy for midodrine in these pediatric studies was 66% (95% CI 41-87%) 
(Figure 2.2), with evidence of statistical heterogeneity across studies (I2=81.7%, P=.004). 
Comparable data on the symptomatic response to midodrine in adults that meet the review 
criteria was lacking. The poor efficacy of droxidopa was based on a retrospective review of a 
single center’s experience and was unsurprising given that most of these patients had 
previously failed to respond to other vasopressors. (140) Of the 40 patients known to have 
commenced droxidopa, only 10 patients reported improvements at the time of the review. 
Octreotide was also utilized in treatment-resistant patients. The exact efficacy was difficult to 
ascertain (between 50-100%) due to combined reporting of outcomes for all patients with 
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Figure 2.2: Meta-analysis of studies of the individual therapeutic modalities beta-receptor 
blockers, ivabradine, midodrine, and exercise. Proportion of responders to: (A) 
Cardioselective beta-receptor blockers; (B) Non- cardioselective beta-receptor blockers; (C) 
Ivabradine; (D) Midodrine and (E) Exercise  
 





Heart rate reduction 
 There were 10 publications describing symptomatic response over at least 4 weeks 
after interventions directed toward rate control (Table 2.2). The rate control agents included 
cardioselective beta-receptor blockers (1 small RCT, 5 case series, 151 
patients),(23),(138),(142),(143),(144),(145)  non-cardioselective beta-receptor blockers (1 
small RCT and 1 case series, 16 patients), (22),(146) and ivabradine (2 case series, 45 patients). 
(111),(147) None of the studies reported on treatment efficacy in patients with 
hyperadrenergic POTS specifically. The pooled efficacy was 60% (95% CI, 52%-69%; I2=0%, 
P=.72) for cardioselective beta-receptor blockers (Figure 2.2 [A]) and 51% (95% CI, 16%-86%; 
I2=50.5%, P=.16) for noncardioselective beta-receptor blockers (Figure 2.2 [B]). There was no 
evidence of publication bias amongst studies reporting efficacy of cardioselective beta-
receptor blockade (P=.64). Notably, there was no statistically significant difference between 
the symptomatic response in patients receiving beta-blockade compared with patients 
receiving placebo (22),(25) or conventional therapy (23) (salt supplementation) in the 2 small 
RCTs. The overall efficacy for ivabradine was 64% (95% CI, 47%-80%; I2=24.7%, P=.25) (Figure 
2.2 [C]). (111),(147) There is a lack of head-to-head studies between ivabradine and beta 
receptor blockade for the treatment of POTS. However, the negative beta-blockade RCT and 
the higher proportion of treatment-resistant patients in the ivabradine case series suggest 
that ivabradine may be superior. An RCT adequately powered to compare these different rate-
controlling strategies in both hyperadrenergic and neuropathic cohorts may help clarify the 
role of these agents in the treatment of POTS. 
 





Legend Table 2.2: Heart Rate Reductiona  
 
 
abid = twice daily; NA = not available; OD = once daily; SF-36 = 36-item Short Form Health 
Survey; tid = 3 times per day; WFDI = Walker Functional Disability Inventory; WSS = Winker 
symptom scale 
bHeyland Methodological Quality Score of 8 or greater denotes high quality; all other studies 
graded 4 using the rating score modified from the Oxford Centre for Evidence-Based 
Medicine represent case-series or case-controlled studies 
cPatients may be utilizing other therapies e.g. dietary salt & water 
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Table 2.2: Heart Rate Reductiona  
 
 





 The 3 exercise intervention studies included a small RCT (31 patients) (107) and 2 case 
series (Table 2.3). (22),(104),(148) The 15 patients in the control arm of the RCT were well 
matched to the 16 patients undergoing a 3-month program of jogging. Both groups had access  
to the same army diet and undertook similar activities, with the treatment group also 
performing 30-minute jogging sessions 3 times each week (gradually increased to 50 minutes 
per session by the third month) at a speed tailored to maintain the target training heart rate, 
defined as resting heart rate + 0.6 x (maximal - resting heart rate). Efficacy of exercise training 
in the RCT of male army recruits was 63%. (107) In the first case series (with information 
presented in 2 separate publications), 25 participants were enrolled in a supervised exercise 
program (accompanied by advice to increase salt and water intake). (22),(104) The reported 
100% efficacy for the 3-month exercise intervention was based on the physical component 
sub-score of the 36-item Short-Form Health Survey (SF-36). However, note that only 19 
participants (of the original 25 enrolled in the study) completed the program and that 23% of 
those, in whom the social functioning sub-score of the SF-36 was recorded, indicated no 
improvement or deterioration. (22),(104) The second case series included 251 POTS registry 
patients provided with an exercise program with no direct supervision. (148) This registry 
study did not report on treatment efficacy according to the number of patients responding. 
Response data were available from only 78 participants (31% of the original cohort of 251 
participants enrolled), making it difficult to place too much weight on the 100% efficacy 
reported in each of the SF-36 sub-scores. (148) The overall efficacy of the exercise intervention 
(not including the registry study) was 72% (95% CI, 55%-86%; I2=6.3%, P=.30) (Figure 2.2 [E]). 
 





 Two case series have been published on the use of erythropoietin to manage 
symptoms in patients with POTS (Table 2.3). The smaller series combined erythropoietin with 
iron supplementation and reported improvement in 3 of the 8 patients. (149) The larger case  
series was a retrospective medical record review in which 71% efficacy was reported in a 
treatment-resistant population. (118) The group reporting on a retrospective chart review of 
outcomes after droxidopa therapy also reported on outcomes after an acetylcholinesterase 
inhibitor (pyridostigmine), (120)  a dopamine reuptake inhibitor (modafinil) (119) and a 
catecholamine uptake inhibitor (methylphenidate) (120) with respective efficacy of 51%, 60% 
and 77%, respectively (Table 2.3). Thirty-five patients (17%) treated with pyridostigmine 
stopped taking the medication due to adverse effects (mainly gastro-intestinal). Four of 7 
patients treated with a closed auditory loop stimulation reportedly improved, (150) whereas 
the case series of patients treated with sinus node modification reported no symptomatic 

























Legend Table 2.3: Miscellaneous Therapeutic Approachesa   
 
abid = twice daily; EPO = erythropoietin; FeSo4 = ferrous sulfate 300mg tid; NA = not available; RCT = 
randomized controlled trial; SC = subcutaneous; IU = international units; SQ(10), SQ (14) = symptom 
questionnaire rating 10 and 14 symptoms respectively; SF- 36 = 36-item Short Form Health Survey; 
SQ (10), SQ(14) = symptom questionnaire rating 10 and 14 symptoms, respectively; SR = slow 
release; tid = 3 times per day; WSS = Winker symptom scale (48) 
bCombined with increased salt and water and raised head of bed;  
cA total of 78 of 205 patients (31%) completed the SF-36  
dResults reported by symptoms rather than by individual 
eHeyland Methodological Quality Score ≥8 denotes high quality; all other studies graded 4 with the 
Oxford Centre for Evidence-Based Medicine represent case-series or case-controlled studies;   
fA total of 41 of 60 patients with orthostatic intolerance had postural tachycardia syndrome on 
orthostatic stress testing, but results are not reported separately for the subgroup of patients with 
postural tachycardia syndrome  
  






 This systematic review identified 28 publications describing symptomatic responses 
after at least 4 weeks of treatment in 858 patients with POTS with the following key findings. 
First, there is a paucity of RCT data, with efficacy information from only 103 patients 
randomized in the 3 RCTs. (22),(23),(107) Second, therapy directed at intravascular volume 
expansion or heart rate reduction was associated with similar mean rates of efficacy (60-70%) 
in treatment-naive patients from both case series and limited RCT data. Third, the evidence 
for use of vasopressors in patients with POTS primarily involves use of low doses of midodrine 
in children, with the mean efficacy of approximately 65%. Fourth, exercise training seems 
efficacious in approximately 70% of patients with POTS who can tolerate the regimen. Last, a 
host of miscellaneous therapies have been given to small cohorts of treatment -resistant 
patients to variable effects. Many of the medications directed at increasing intravascular 
volume or vascular tone and controlling heart rate are relatively standard therapies for 
patients with POTS, as reported in several large series. (123–126, 151) This review identified 
an overall limited evidence base for POTS therapies, with significant heterogeneities seen in 
terms of age and symptom severity of included patients and the measures used to determine 
treatment efficacy. 
 
Tolerability of POTS Therapies 
 Whilst reviewing treatment efficacy, we noted that the occurrence of adverse events 
and adverse effects were rarely reported. The efficacy estimates are predominantly based on 
the outcome of patients who continued the intervention rather than by intention to treat.  
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Patients who ceased therapy are likely to have done so due to either lack of effect or 
experiencing an adverse effect. It is likely, therefore that omitting to report intention to treat 
numbers has inflated efficacy results. Publication bias may also have contributed to an 
overestimate of efficacy in the case series as suggested by the greater benefit from beta-
receptor blockade in the case series than that seen in the RCT of propranolol. (22, 23)  
 
Evaluating Response to Therapy: Need for a Standardized Tool 
 Notably, 11 of the 28 publications did not use any tool to measure symptomatic 
response, relying on retrospective review of standard clinical assessment. The remaining 
studies used a variety of questionnaires for assessing symptomatic response to therapies, with 
a variable emphasis on QOL domains and frequency or severity of symptoms. The SF-36 sub-
scores for physical and social functioning were used to assess symptomatic outcomes in 4 
studies. (22),(104),(112),(148) Two studies adopted alternative tools for assessing QOL. The 
first of these used a questionnaire developed at the Children’s National Health System that 
consisted of 25 questions in 8 major domains. (137) The single-centre retrospective postal 
survey of patients who had previously undergone autonomic reflex testing used the Walker 
Functional Disability Inventory, which contains 15 questions related to daily activities. (138) 
Eight studies based efficacy assessment on scores generated by summing the frequency of 
symptoms. Six of these used a scale validated for adults during occupational assessments, 
referred to in tables 1 through 4 as the Winker symptom scale (WSS). 
(23),(107),(139),(143),(144),(145) Similar study-specific tools were used in the other 2 studies. 
(115),(136) Three studies used tools assessing the severity of symptoms, including study- 
 
 




specific questionnaires (29),(141),(150) and the Orthostatic Hypotension Questionnaire, (112) 
previously validated for adults with neurogenic orthostatic hypotension. (49)  
 
 Objective assessment of symptomatic response to POTS therapies using reliable and 
validated QOL questionnaires is important because it is well recognized that the correlation 
between physiologic data, such as orthostatic heart rate increment, and a patient’s severity 
of symptoms is highly variable. (154) Favourable symptomatic response may not be 
accompanied by the control of heart rate. Furthermore, reduced orthostatic heart rate 
increase may not beget symptomatic improvement. (22, 115)  Symptoms in many patients 
with POTS may improve over time regardless of therapy. (123) Several confounders may also 
interfere with assessment of the true treatment efficacy, including the potential for placebo 
effects and the inadequacies of some of the symptom tools used. Standardization of QOL and 
symptom burden tools used at baseline and endpoint analysis will greatly improve our ability 
to evaluate the efficacy of various interventions over time.  
 
Refining POTS Therapies: Potential Role of Biomarkers 
 Due to heterogeneity in the pathophysiology underlying POTS, biomarkers may play 
an incremental role in refining therapy. For example, an RCT found that midodrine was 
superior only to placebo in reducing orthostatic heart rate increase in the subgroup of patients 
with peripheral venous pooling (based on calf blood flow measures). (64) Other biomarkers 
that may be useful in delineating responders to specific therapy include plasma C-type 
natriuretic peptide,(143) noradrenaline,(144) copeptin, pro-adrenomedullin(139) and 
measures of plasma volume and 24-hour urinary salt excretion. (145) Further studies are  




needed to validate these and other novel biomarkers that may guide the physician in choosing 
the best individualized treatment option. 
 
Need for Improved Collaborative Research 
 This lack of quality data on the efficacy of various therapies for POTS is in keeping with 
the obvious lack of class I recommendations or Level A evidence in the recent expert 
consensus statement from the Heart Rhythm Society. (109)  Of note, the class IIa 
recommendation of acute IV infusion for short-term clinical decompensation has a low level 
of evidence and is derived from studies with less than 4 weeks of follow-up that are not 
included in this review. (54),(156),(157),(158) Evidence has become available since the 
publication of the consensus statement, regarding regular IV saline infusions via long-term or 
repeated IV cannulations that conferred high efficacy in treatment-resistant patients. (112) 
Most of the consensus statement recommendations are at class IIb (benefits equivalent to or 
possibly exceeding harm), with several stemming from consensus opinions rather than from 
published evidence. The management of POTS in the real world is likely to be highly variable 
and physician dependent. With the lack of quality data, the outcome of patients with POTS 
can vary greatly, hinging on the experience of the treating physician.  
 
 Although the consensus statement may help to guide therapies, this review highlights 
the urgent need for more systematic and collaborative research as well as shared patient 
registries to improve the evidence base for POTS therapies. (24) We suggest that future 
studies be designed to address the following considerations: (1) need for homogenous patient  
 




groups in relation to pathophysiology (neuropathic vs. non neuropathic); (2) use of a 
standardized, validated questionnaire to assess severity and frequency of symptoms of 
orthostatic intolerance; (3) use of a quantitative measure of heart rate increment and 
symptoms of orthostatic intolerance during tilt or standing test; (4) monitoring of fluid and  
salt intake; (5) monitoring of exercise activity; (6) duration of follow-up of at least 6 months; 
and (7) use of biomarkers. 
 
Conclusion  
 Good-quality evidence for the management of patients with POTS is lacking. Case 
series and small RCTs of interventions directed at increasing intravascular or blood volume, 
increasing vascular tone, controlling heart rate, and increasing exercise tolerance 
demonstrate moderate efficacy. More research is urgently needed to improve the evidence 
gap in the management of this complex condition.
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In this chapter, our pilot study is described. In this pilot study, we followed a protocol used in 
a study of neurovascular coupling in which patients with spinal cord injury were found to have 
a less robust increment in posterior cerebral blood flow velocity in response to a visual 
stimulus when compared with a control group. (1) The difference in CBFv response was 
attributed to disruption of autonomic reflexes in the cohort with spinal cord injuries. As 
patients with POTS report significant symptom scores related to autonomic function, we 
undertook this study to identify if patients with POTS had similar deficits to those seen in the 
patients with spinal cord injury. Using a handheld ultrasound probe to measure CBFv from the 
posterior cerebral artery during brief visual stimuli, we did not find any difference between 
CBFv responses in the POTS group when compared with the control group, however. In this 
study we also piloted a number of cognitive tasks, gaining insight into problems that might be 





Background: Cognitive difficulty, often described as “brain fog”, is a prevalent complaint 
amongst patients with postural tachycardia syndrome (POTS). It remains unclear whether 
brain fog is related to impaired cerebral blood flow (CBF) in POTS.  
Methods: We assessed CBF in the posterior cerebral artery (PCA), using transcranial Doppler 
ultrasound, in response to visual stimuli. CBF was recorded in 11 POTS subjects and 8 healthy 
controls whilst they rested with eyes closed in a seated position and following the direction 
to open their eyes.  A series of neurocognitive tasks were then undertaken.  
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Results:  CBF parameters were similar between the two groups. POTS patients demonstrated 
significantly longer latency in delayed match to sample response time and greater errors in 
attention switching task.  
Conclusions: Impaired short-term memory and alertness may underlie the symptom of brain 





 Postural tachycardia syndrome (POTS) is a chronic debilitating condition in which 
symptoms of orthostatic intolerance (OI) are accompanied by a sustained increase in heart 
rate >30 beats per minute (bpm) within 10 minutes of orthostatic challenge. (8),(78) Current 
available treatments for POTS demonstrate only moderate efficacy with limited evidence 
base. (9),(24),(109) Cognitive difficulty, often described as “brain fog”, is a prevalent complaint 
amongst patients with POTS. Ninety-six percent of the 138 patients with POTS responding to 
a questionnaire on the symptoms of brainfog indicated they had significant symptoms 
described as “forgetful”, “difficulty thinking”, “difficulty focussing”, “cloudy” and “difficulty 
finding the right words or communicating”.  (81) Interestingly, brain fog has been reported to 
occur even in the supine position, and may not be limited to upright posture. (82) Others have 
demonstrated approximately 25% increase in cerebral blood flow (CBF) velocity in the 
posterior cerebral artery (PCA) of healthy individuals in response to visual stimuli. (1) 
However, the CBF pattern and its response to visual stimuli have not been investigated in POTS 
individuals while seated. Here, we hypothesized that POTS individuals have impaired CBF 
regulation as well as cognition to explain the symptom of brain fog when seated.   
  






 Consecutive patients with POTS (confirmed with 10-minute orthostatic challenge) and 
complaint of brain fog (difficulty thinking/focusing/communicating, forgetful and cloudiness) 
were studied. (81) All subjects remained on their usual POTS treatments (Table 3.1). 
Additionally, eight age-matched healthy volunteers, who were not on any regular 
medications, were studied. All subjects had abstained from caffeine or alcohol for 24 hours 
before the study. All studies were undertaken between late morning to mid-afternoon. 
Participants provided written informed consent. This study has institutional ethics approval. 
 
 Colour TCD with sonography was used to assess CBFv in the PCA. A 2MHz phased array, 
handheld transducer was used along with a portable ultrasound unit (SonoSite Edge, SonoSite 
Inc., Washington, USA). Participants were asked to sit quietly with their eyes closed for 1 
minute. The temporal bone was used as an acoustic window. Using the duplex images, the 
echogenic thalami were located and used as a landmark from which the circle of Willis and 
subsequently the PCA was identified. The pulsed wave Doppler mode was used to generate a 
real-time image and spectral waveform of CBF. Measurements of CBF velocity were taken at 
baseline with eyes closed for 1 minute and for a 10-second interval after the subject was given 
the instruction “open your eyes”. This process was repeated five times with all recordings 
analysed for percentage changes, between eyes closed and eyes opened, in peak systolic 
velocity (PSV), end diastolic velocity (EDV) and time averaged peak (TAP). The TAP parameter 
represents the mean flow velocity over an integral number of cardiac cycles.  
 
 




 Each participant was then asked to complete a series of neurocognitive tests (CANTAB: 
Cambridge Neuropsychological Test Automated Battery, Cambridge Cognition Ltd., 
Cambridge, UK) to assess executive function, reaction time (RT), memory and attention. These 
tests are described in greater detail in Chapter 1 and video demonstrations of the tasks can 
be viewed online. (101) Briefly, they involved a test of RT in which subjects were instructed to 
touch a signal as quickly as possible as it appeared in different positions on the iPad screen. 
This was followed by: rapid visual information processing task (RVIP): when subjects were 
asked to identify pre-defined 3 digit sequences amongst rapidly appearing random numbers 
on the screen; delayed match to sample task (DMS): when subjects were asked to match a 
series of complex geometric coloured patterns with one of four patterns appearing on the 
screen after the target sample had been hidden for up to 12 seconds; and attention switching 
task (AST): when subjects were assessed on the ability to ignore irrelevant information when 
responding to a question. The total time taken to complete the assessment (including 
instructions and non-assessed training phases for each module) was approximately 45 
minutes.  
 
 Data was analysed in GraphPad Prism 7 (La Jolla, California, USA). Data that was not 
normally distributed was analyzed using the Mann Whitney U test. Categorical data was 
compared using chi-square analysis. A single outcome measure for latency and errors was pre-
defined for each neurocognitive task to avoid the need to use a Bonferroni (or similar) 
correction in interpreting the many outcomes provided by the CANTAB program.  Statistical 
significance was taken as p<0.05.  
  






 Nine of the 11 (82%) POTS patients were female compared with 4 of the 8 (50%) 
controls, with median age of 28 and 31 years old respectively (both p=NS). Detailed 
medications use is shown in the Table. Five of the 11 POTS patients were not on 
fludrocortisone, midodrine or heart rate slowing medications. Baseline PSV and percentage 
increment of all CBF velocity parameters with visual stimuli were similar in the PCA of POTS 
individuals versus healthy controls (Table; all p=NS). 
 
 POTS individuals had a significantly longer latency in DMS response (3.6 vs. 2.5 
seconds, p=0.04) and achieved lower number of correct responses during AST as compared to 
healthy controls. However, the median latencies for the RT, AST, and RVIP tasks were not 
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Age, years (Median, IQR) 28 (19-37) 31 (26-35) 0.3 
Female, n (%) 9 (82) 4 (50) 0.1 

















Baseline peak systolic velocity, cm/s (IQR) 54 (43-68) 49 (49-52) 0.8 
Cerebral blood flow parameters:  
percentage increment with visual stimuli, % (Median, IQR) 
Time averaged peak  21 (15-27) 22 (16-24) 0.9 
Peak systolic velocity  15 (12-21) 14 (9-18) 0.7 
End diastolic velocity  21 (13-24) 17 (12-45) 0.9 
Neurocognitive parameters: at rest and seated (Median, IQR) 
Reaction time, ms 214 (173-271) 227 (200-267) 0.4 
Rapid visual information processing latency 
(ms) 
437 (397-498) 437 (410-474) 0.8 
Delayed match to sample  
- latency (ms) 












Attention switching task 
- latency (ms) 











IQR: inter-quartile range. Neurocognitive tests: the reaction time is the time taken to touch a 
signal as quickly as possible as it appeared in different positions on the iPad screen. The 
rapid visual information processing test involved identification of pre-defined 3 digit 
sequences amongst rapidly appearing random numbers on the screen. The delayed match to 
sample test instructs the subject to identify which of 4 images provided matches the target 
image shown previously. The attention switching task instructs the subjects to touch the 
correct response to answer a prompt work that appears above an arrow. It measures the 
subject’s ability to ignore irrelevant information when responding to a question. Latency is 
the time taken to touch the correct response. 
  






 This study demonstrated objective evidence of neurocognitive deficits in POTS 
individuals but similar increment in CBF velocity parameters in response to visual stimuli in 
the PCA of both groups. Others have demonstrated a correlation between increment in CBF 
in the middle cerebral artery (MCA) during cognitive challenge (functional hyperaemia) and 
the ability of POTS patients to recall numbers. The deficit in functional hyperaemia became 
much more pronounced when the cognitive challenge was performed concurrently with 
orthostatic challenge, suggesting impairment of both neurovascular coupling and 
autoregulation. (82) Autoregulation is the maintenance of a relatively constant cerebral 
perfusion pressure despite significant fluctuations in peripheral blood pressure. 
Autoregulation tends to deteriorate in patients with POTS during orthostatic challenge, as 
oscillations in peripheral blood pressure become more marked. (82),(83) We found normal 
CBF velocity response in the PCA to visual stimuli in POTS patients whilst remaining seated. 
However, it remains unknown whether CBF changes would differ if measured in other vessels, 
such as the MCA, or with more complicated visual search paradigms. (159)   
 
 There has been an increasing awareness of cognitive dysfunction in POTS patients. To 
date, formal neurocognitive assessments in POTS patients remain limited with variable 
findings of deficits in memory, attention and executive function using different 
neuropsychological testing tools. (160) We found deficits in short-term memory and alertness 
in our POTS cohort in the seated position. In contrast, others have shown impaired selective 
attention and cognitive processing but unaffected memory in POTS patients using different 
neuropsychological tests. (161) This may be due to the heterogenous nature of the condition  
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and the many factors such as sleep disturbances, chronic fatigue and medication use, that 
may influence different facets of the cognitive status. These objective measures of cognitive 
dysfunction may in part explain the brain fog described by POTS patients even when 
recumbent, although the mechanisms remain unclear. (81)     
   
Study limitations 
 We used a portable ultrasound setup with a handheld transducer to assess the ability 
to detect changes in CBFv during the brief period in which changes in blood flow occur in 
response to the increase in cerebral metabolic demand following the visual stimulus of 
opening the eyes. Headgear fixation of the ultrasound probe would have provided the 
additional ability to measure changes in CBFv during the prolonged period of cognitive testing 
but would have changed the test from being a widely accessible clinical tool to the less 
accessible research measure.  
 
 Using the MCA instead of the PCA may have increased the reliability of maintaining a 
constant angle of insonation. However, the increment in CBFv in the PCA following a visual 
stimulus is much greater than in MCA, not only because of the smaller diameter of the vessel, 
but because the visual cortex is supplied by the PCA. The 21% increment in the PCA CBF 
velocity following visual stimuli seen in our study is in keeping with a previously published 
figure of 25% seen in healthy controls.[8] This magnitude of change seen in the PCA warrants 
its selection over the larger and technically easier MCA, where the comparative change is 
much lower at 4%.[7]     
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 Although hypocapnia can alter cerebral and peripheral vascular tone, it is unlikely that 
measurement of end-tidal carbon dioxide (ETCO2) levels would have contributed greatly to 
our study as the simple eye opening task and the brevity of the period during which the eye-
opening stimulus effects CBFv (maximal during the first 10 seconds) is unlikely to have resulted 
in significant changes in ETCO2.  
 
 It is unclear if the continued administration of the usual POTS medications may have 
altered the CBFv changes in response to visual stimuli. Discontinuation of these medications 
may itself have skewed results as discontinuation can precipitate rebound changes in 
intravascular volume, HR and vascular tone which could also have confounded interpretation 
of CBFv responses to stimuli. Furthermore, the removal of therapeutic agents may have 
overemphasized differences in cognitive performance between POTS and control groups. The 
decision to continue treatment allowed us to identify differences in cognitive ability between 
POTS and control groups even with maximal therapy. We acknowledge that factors for which 
we did not control including education level, intelligence, sleep deprivation and mental health 
conditions may have contributed to the differences seen in results from cognitive assessment. 
(162) In addition, there may be greater cerebral activation with less lateralisation in females.  
(163) The lack of significance in some cognitive parameters may be due to the small number 
of POTS subjects in this study. 
 
Conclusion 
 POTS patients demonstrate normal CBF velocity increment in response to visual stimuli 
when seated. Impaired short-term memory and alertness may reflect the symptom of brain 
fog in POTS patients.   
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Chapter 4: Cerebral blood flow and cognitive performance in postural 
tachycardia syndrome: Insights from sustained cognitive stress test  
 
 
Contextual  Statement 
 
 During the pilot study we had noted the POTS group became notably fatigued whilst 
performing cognitive tasks. We wished to determine if the prolonged cognitive stress was 
associated with a deterioration in cerebral blood flow response to the prolonged cerebral 
metabolic demands. We had measured CBFv changes in the PCA during the pilot study, 
which was appropriate to the cerebral regions activated by the brief visual stimulus and the 
expectation of a robust increase in CBFv as reported by others (>20% increase in CBFv in the 
PCA) when compared with the MCA (~3% increase in CBFv in the MCA). (1)  
 
 In this study, changes in CBFv in the middle cerebral artery (MCA) was measured 
despite the expectation that the relative change in CBFv associated with cerebral activation 
would be lower in the MCA than in the PCA. This decision was based on both the fact that 
the larger diameter of the MCA would improve our ability to maintain a constant angle of 
insonance (critical in comparing changes in CBFv over time), as well as the knowledge that 
the cerebral region supplied by the MCA would be activated during cognitive stimuli.  
 
 We maintained the angle of insonance in the MCA through use of headgear fixation. 
The equipment utilized to record the physiological changes during the prolonged cognitive 
stress required the use of a dedicated facility. In comparison, during the pilot study, we were 
able to adapt readily to facilitate measurement of CBFv in a variety of settings through the 
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use of a portable ultrasound and handheld probe. The dedicated facility had the additional 
advantage of allowing simultaneous recording of participants’ heart rhythm, respiratory rate 
and end tidal carbon dioxide (ETCO2), which allowed us to determine if hypocapnia was 
contributing to changes in CBFv.  
 
 In the development of this study protocol, a decision was made to allow patients to 
continue their usual medications with the exception of the short acting vasopressor, 
midodrine. We excluded midodrine on the basis that the short half-life resulted in complete 
washout of the vasopressor every night . We did not, therefore, expect to see any rebound 
changes in CBFv responses by withholding this medication. The rapid onset of action of 
midodrine also lent itself to a direct study of the vasopressor’s effect on CBFv in response to 
prolonged cognitive stress (reported in Chapter 5). By allowing patients to continue their 
other medications we may have increased the chance of creating a difference between the 
groups as a result of reduced sympathetic activation (in the case of beta-blockade), or 
impaired concentration (in the case of anti-anxiety or anti-depressant medications). Ceasing 
these medications may have also clouded interpretation of our results, however, as 
withdrawal of beta-blockade may result in rebound tachycardia, and withdrawal of anti-
anxiety or anti-depressant medications may impair cognitive performance through sleep 
deprivation and mental health consequences.   Bearing this in mind, we opted to allow 
patients to continue these medications. We did not measure sleep deprivation or level of 
education in our study, both of which may have impacted on cognitive performance.  
 
 We demonstrated a greater fall in CBFv in the MCA in the POTS group during the 
course of prolonged cognitive stimulus, however the magnitude of fall was significantly less 
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than the 50% reduction in CBFv previously quoted as the change likely to produce cerebral 
hypoperfusion,(96) which may reflect the more subtle changes in cognitive ability as 







 Individuals with postural tachycardia syndrome (POTS) often experience a number of 
debilitating cardiovascular, gastrointestinal and neuropsychologic symptoms in addition to 
their intolerance to standing. (164) Although it is quite clear that symptoms are related to the 
assumption of upright posture in these individuals,(26) a myriad of factors that reduce blood 
volume (104),(165) or decrease vascular tone (such as hot environments, large meals, physical 
exertion, cardiac deconditioning and medications) are known to exacerbate POTS symptoms 
and interfere with activities of daily living. (26),(164),(166) The impact of these symptoms on 
quality of life and cognitive dysfunction has been well described, however treatment options 
remain limited. (9) Correction of dehydration, exercise training, and manipulation of 
vasoactive and heart rate slowing medications may provide some symptomatic relief, 
however improvement in therapeutic approach will require a better understanding of the 
underlying heterogenous pathophysiology. (9),(109)  
 
  Cognitive dysfunction in patients with POTS is sometimes attributed to concurrent 
anxiety and depression, (167) although performance in tasks requiring sustained attention 
and short term memory has also been shown to deteriorate with orthostatic stress. (82),(167) 
The association of cognitive dysfunction with upright posture may relate to a more 
pronounced reduction in cerebral blood flow (CBF), (98) or oscillations in blood pressure and 
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CBF velocity (CBFv). (82) However, the persistence of mental fatigue and cognitive 
disturbances (“brain fog”) even in a recumbent position, have been reported in POTS. (161) It 
remains unclear whether these symptoms can be explained by abnormal cerebral perfusion 
in the absence of orthostatic stress. We therefore hypothesize that CBFv is reduced in POTS 
patients when they are subjected to prolonged cognitive stress performed in the seated 




 We evaluated cognitive and hemodynamic responses (cardiovascular and cerebral) at 
baseline, after initial cognitive testing and after prolonged (30 minutes duration) cognitive 
stress whilst seated as well as after orthostatic stress (5 minutes standing) in consecutively 
enrolled participants with POTS (POTS group). (Figure 4.1) We compared these with a cohort 
of age and sex-matched healthy participants (Control group). This study was approved by the 
institutional human research ethics committee and conformed to the Declaration of Helsinki. 
All participants provided written, informed consent prior to their inclusion in the study. 
 
Study eligibility and enrolment  
 POTS individuals were enrolled from our autonomic clinic, where specific clinical 
criteria were met: symptoms produced by upright posture with resolution when recumbent 
for at least 6 months in duration, as well as documentation of a sustained increment of heart 
rate of >30 bpm during HUT or within 10 minutes of standing, without a postural blood 
pressure drop of >20 mmHg. These symptoms included light-headedness, headache, fatigue, 
neurocognitive deficits, palpitations, nausea, altered vision, shortness of breath, or sensation  
 




of heat while upright, with no other medical explanation for the symptoms. All POTS patients 
were on treatment in accordance with current guidelines. (109) There were no clinical 
exclusion criteria. The control group consisted of age- and sex-matched healthy volunteers 




Figure 4.1: Study Protocol  
Sequence of physiologic and cognitive measurements during the entire study protocol.  
RT: reaction time, RVIP: rapid visual information processing, OHQ: orthostatic hypotension 
questionnaire, COMPASS-31: Composite Autonomic Symptom Score-31, MSA-QoL: Multiple 
System Atrophy-Quality of Life.




Patient preparation  
 All testing sessions were performed in the morning, with patients abstaining from 
alcohol and caffeine over the preceding 24 hours. No changes were made to POTS treatment 
in the preceding month. Participants were permitted to continue all their usual medications 
except for vasopressors. Patients who usually took midodrine (α-adrenergic agonist, half-life 
of 3 hours) in the morning were asked to delay this dose until after completing the study, 
allowing an interval of at least 15 hours (5x half-life) to elapse from the last dose, to avoid 
exogenous vasopressor therapy confounding interpretation of the study results. The study 
protocol was performed in a climate-controlled facility (22°C), with participants seated at a 
desk, emulating normal (school or clerical) working conditions.  
 
Physiological measurements 
 We used transcranial Doppler (TCD) to measure CBFv from the middle cerebral artery 
(MCA) of the dominant hemisphere (Doppler-BoxX, Compumedics DWL, Singen, Germany). A 
2-MHz transducer probe (PW, Compumedics DWL) was fixed in place over the transtemporal 
window using adjustable headgear (DiaMon, Compumedics DWL) to minimize movement of 
the probe during the study protocol. CBF velocity was recorded continuously throughout the  
study protocol. A single-lead electrocardiogram (FE132 Bioamp, ADInstruments Pty Ltd, NSW, 
Australia) was placed for continuous monitoring. Continuous, non-invasive beat-to-beat 
hemodynamics (heart rate; HR, blood pressure; BP) were also obtained using a cuff placed on 
the finger (photoplethysmography; Finapres Medical Systems BV, Enschede, The 
Netherlands). A chest wall strain gauge (MLT 1132/D Piezo Respiratory Belt Transducer, 
ADInstruments) was used to measure respiratory rate (RR). Lastly, end-tidal carbon dioxide  




(ETCO2) was measured (Capnostream 20P, Medtronic, Minneapolis, MN, USA) via nasal prongs 
with mouth scoop (Smart CapnoLine Plus, Microstream, Medtronic). The CBFv wave envelope, 
electrocardiogram, beat-to-beat BP waveform & heart rate, ETCO2 and respiratory rate data 
were all recorded simultaneously through a data acquisition device (Powerlab PL35/16, 
ADInstruments) connected to a personal computer using data acquisition software (LabChart 
8, ADInstruments). All data was exported to MATLAB (MathWorks, Natick, MA, USA) for 
further analysis. 
 
Neurocognitive assessment  
 We performed cognitive testing using an iPad-based (Apple Inc, Cupertino, CA, USA) 
software collection tool (Cambridge Neuropsychological Test Automated Battery - CANTAB; 
Cambridge Cognition, Cambridge, UK). (101) Specifically, we assessed the cognitive domains 
of psychomotor speed and attention by measuring reaction time (RT) and rapid visual 
information processing (RVIP) respectively. In brief, the RT test measures the time taken to 
release an on-screen button and touch a target in response to a programmed visual stimulus. 
It measures the speed of both motor and mental response. The RVIP task assesses the 
subject’s ability to identify a target sequence from a series of numbers that flash up in a 
pseudo random order onto the iPad screen at a rate of 100 numbers per minute as a measure 
of sustained attention. Both RT and RVIP were measured at baseline and after 30 minutes of 
prolonged cognitive stress test (PCST) (Figure 4.1).  
 
 The two CANTAB tasks used to produce cognitive stress were: delayed matched 
samples task, which involves recall of complex patterns, and attention switching task, which 
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requires a motor response to rapid visual changes in the position and direction of an arrow 
that appears on the screen. Data are presented as mean ± standard deviation or median (Q1, Q3). 
OHSA is the symptom assessment component of the OHQ questionnaire used to quantify symptoms 
present at the time the questionnaire was completed. (49) Six symptoms are given a score from 0 
(symptom not present) to 10 (most severe), with a maximum total score of 60. The COMPASS-31 
(adjusted) score is a validated score calculated from the raw COMPASS 31 score after applying a 
weighting that takes into account the number of points and relative importance of organ systems to 
the assessment of autonomic dysfunction. (47) A high score indicates greater severity of symptoms 
related to autonomic dysfunction. The MSA-QoL score assesses factors that impact on quality of life 
with a high score indicating significant impairment in quality of life. (168) 
 
Symptom assessment 
 In order to assess acute changes in symptoms we asked participants to rate their 
symptoms using the Orthostatic Hypotension Questionnaire (OHQ)  (49) with the Likert scale 
(from 0-10; least to most severe), at baseline and after the prolonged cognitive stress testing. 
The symptoms assessed were: dizziness, light-headedness or feeling faint; problems with 
vision (blurring, seeing spots, tunnel vision); weakness; fatigue; trouble concentrating; and 
head & neck discomfort. While the OHQ refers to symptoms experienced over the preceding 
week, we adapted it to assess immediate symptoms.  
 
In addition to assessing current symptoms, all participants were also asked to 
complete questionnaires at completion of all physiologic measurements to determine their 
quality of life and autonomic symptoms in the preceding month. The MSA-QoL (Quality of life 
assessment in Multiple System Atrophy) questionnaire was used to assess quality of life. (168) 
Although not specifically designed for POTS, it has been well validated as a patient reported  
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outcomes tool. Further, autonomic symptoms were assessed using the well validated, 
abbreviated Composite Autonomic Symptom Score (COMPASS- 31). (47)   
  
Statistical Analysis 
 Normally distributed variables were presented as mean ± standard deviation while non 
normally distributed variables were presented as median and interquartile range (Q1, Q3). 
Categorical variables were expressed as numbers and percentages. We used averaged 
physiologic data over 30 seconds at the following time points for comparison: at baseline 
whilst seated, whilst undertaking the initial cognitive testing and undertaking repeat cognitive 
testing after 30 minutes of PCST whilst seated, and during the 5-minute stand test. A mixed 
effects model was used to assess group (POTS, controls) and condition (baseline vs. initial 
cognitive test, initial cognitive test vs. post PCST, baseline vs. orthostatic stress) as main effects 
and interaction between group and condition. Individual patient was modeled as random 
effect to account for repeated measures within individuals between the conditions. Model 
residuals were visually inspected for normality to ensure an appropriate model fit. Statistical 
tests were performed using SPSS Statistics (version 24, IBM corp, Armonk, NY, USA) and 





 We enrolled 40 participants with n=22 with POTS and n=18 healthy sex- and age-
matched controls. Baseline characteristics such as medication usage, seated physiologic and 
cerebral blood flow parameters are presented in Table 4.1. Notably, the POTS group has 
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higher resting HR whilst seated than the controls (90±14 vs. 74±9 bpm; p=0.01). There was no 
difference in mean resting BP, RR, ETCO2 and CBFv between the groups whilst seated at rest. 







Clinical characteristics  
Age (years) 29±11 28±13 0.8 
Female, n (%) 19 (86) 13 (72) 0.4 
















Physiologic measurements (at rest and seated) 
Heart rate (bpm)  90±14  74±9 0.01 
Systolic BP (mmHg)  112±12 110± 9 0.6 
Diastolic BP (mmHg)  78± 12 78±10 0.9 
Pulse pressure (mmHg) 34±11  32±7 0.7 
Respiratory rate (breaths/min)  17±3 17±3 0.7 
ETCO2 (mmHg) 35±4 36±3 0.4 
CBFv (cm/s) 63.0±13.9 65.3±13.3 0.8 
Quality of life & symptom scores 
OHSA (from OHQ)  19 (16, 24) 0 (0, 2) <0.001 








13 ± 10 
25 ± 9 
20 ± 11 
58 ± 25 
 
0 ± 1 
4 ± 5 
5 ± 9 








POTS: postural tachycardia syndrome, BP: blood pressure, ETCO2: end-tidal carbon dioxide, CBFv: 
cerebral blood flow velocity, OHSA: Orthostatic Hypotension Symptom Assessment, OHQ: Orthostatic 
Hypotension Questionnaire, COMPASS-31: Composite Autonomic Symptom Score-31, MSA-QoL: 
Multiple System Atrophy-Quality of Life. 




Physiologic changes with initial cognitive testing 
 Mean HR was consistently higher in the POTS group (p=0.003) with significant increase 
during initial cognitive testing in both groups (p<0.001) but the extent of increase differed 
between POTS and Control groups (p=0.01, Table 4.2) with a greater increase seen in the 
Control group (9.5 vs. 4.4%, Figure 4.2 A). However, all other physiologic responses (BP, ETCO2 
and CBFv) did not differ between groups from baseline to during initial cognitive testing (all 
p≥0.2, Table 4.2) despite significant increases in systolic & diastolic BP (both p<0.001) and 




Legend Table 4.2: Physiologic and cognitive parameters with cognitive challenges 
 
P value*denotes comparison between POTS and Control groups from baseline to initial cognitive 
testing, P value# denotes comparison between POTS and Control groups from initial cognitive testing 
to post prolonged cognitive stress test, POTS: postural tachycardia syndrome, BP: blood pressure, 
ETCO2: end-tidal carbon dioxide, CBFv: cerebral blood flow velocity. RVIP: rapid visual information 
process, no.: number, Data are presented as mean ± standard deviation. 
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Physiologic and cognitive changes during repeat cognitive testing after PCST 
 HR response during repeat cognitive testing after PCST was similar between groups 
(p=0.7, Table 4.2) with consistent slowing as compared to during initial cognitive testing 
(p=0.04), although POTS patients maintained higher HR than Control patients throughout 
(p=0.005, Figure 4.2 A). Following PCST, CBFv was lower on repeat cognitive testing (p<0.001) 
when compared to during initial cognitive testing and significantly differed between groups 
(p=0.038, Table 4.2) with a larger decrease seen in the POTS patients (-7.8 vs. -1.8%, Figure 
4.2 C). All other physiologic responses (BP & ETCO2) did not differ between groups during 







Legend Figure 4.2: Physiologic and cognitive parameters with cognitive challenges 
The p values in each graph denote comparisons for ^condition (baseline vs. ICT or ICT vs. post 
PCST) in both groups, ~group (POTS vs. Control) and #interaction (between condition and 
group). For ease of illustration, all values plotted are mean ± standard error of the mean with 
uni-directional error bars. 
POTS: postural tachycardia syndrome, ICT: initial cognitive test, PCST: prolonged cognitive 
stress test, RVIP: rapid visual information processing. 
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Figure 4.2: Physiologic and cognitive parameters with cognitive challenges 
 





The effects of PCST on psychomotor speed and attention are summarized in Table 4.2. 
Mean RT was consistently longer in the POTS group (p=0.007) with significant increase when 
repeated cognitive testing was performed following PCST in both groups (p=0.002); however, 
the extent of increase differed between POTS and Control groups (p=0.027, Table 4.2) with a  
longer delay in the POTS patients (6.1 vs. 1.4%, Figure 4.2 E). When cognitive testing was 
repeated after PCST, the number of correct responses in the RVIP test increased in both 
groups (p<0.001; Figure 4.2 F); however, the accuracy was consistently lower in the POTS 
group (p=0.05) with blunted improvement as compared to the Control groups that 
approached statistical significance (p=0.1, Table 4.).  
 
Physiologic changes at end of 5-minute orthostatic stress 
 Orthostatic stress resulted in significant increases in HR (p<0.001), systolic BP 
(p=0.001) and diastolic BP (p<0.001) as well as significant decrease in CBFv (p=0.002) in both 
groups (Figure 4.3 A-D). Notably, HR was consistently higher in POTS patients (p=0.002; Figure 
4.3 A) while the remaining physiologic parameters showed no differences (p≥0.3). However, 
the extent of changes in all physiologic parameters (HR, BP, ETCO2 and CBFv) did not differ 













Figure 4.3: Physiologic changes with 5-minute orthostatic stress 
 
The p values in each graph denote comparisons for ^condition (baseline vs. orthostatic stress) 
in both groups, ~group (POTS vs. Control) and #interaction (between condition and group). For 
ease of illustration, all values plotted are mean ± standard error of the mean with uni-



























P value denotes comparison between POTS and Control groups from 
baseline to post orthostatic stress, POTS: postural tachycardia syndrome, 
BP: blood pressure, ETCO2: end-tidal carbon dioxide, CBFv: cerebral 
blood flow velocity. Data are presented as mean ± standard deviation. 




Symptom and quality of life assessments 
 Overall quality of life scores (MSA-QoL) and symptom scores (COMPASS-31) were 
significantly higher in the POTS group in comparison to the Control group (Table 4.1). At 
baseline, orthostatic hypotensive symptoms were significantly higher in the POTS vs. Control 
groups (p<0.001, Table 4.1). The POTS group demonstrated consistently worse orthostatic 
symptoms (p<0.001) with significant increase in OHSA scores at the end of the entire research 
protocol in both groups (p<0.001) although the extent of increase was greater in the POTS 




 To our knowledge, this study is the first to evaluate CBFv in POTS individuals 
undergoing sustained cognitive challenge whilst seated. We found that following PCST, POTS 
individuals demonstrate cognitive dysfunction of reduced psychomotor speed which was 
accompanied by a significant reduction in CBFv when compared to healthy controls whilst 
remaining seated. Additionally, we found that both groups demonstrated similar reductions 
in CBFv and increments in heart rate following orthostatic stress of 5 minutes duration. 
Interestingly, the CBFv following PCST in the POTS group was not dissimilar to that seen during 
orthostatic stress. In addition, greater increase in orthostatic symptoms were reported by the 
POTS patients as compared to healthy controls at the completion of the entire study protocol. 
Taken together, the decline in CBFv in seated POTS individuals during repeat cognitive testing 
following PCST may explain the common symptom of mental clouding (‘brain fog’) in this 
patient population.  
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Cerebral blood flow and cognition in POTS  
 Systemic blood pressure and heart rate can vary enormously during periods of physical 
stress and orthostasis. It has been postulated that patients with POTS are unable to 
adequately buffer changes in the systemic circulation without compromising cerebral 
perfusion, termed autoregulation. (169) Several studies have evaluated the effect of 
orthostatic stress on cognitive function and cerebral hemodynamics in POTS patients. Ocon et 
al. found a decline in cognitive performance occurring with increasing orthostatic stress in 
patients with POTS and co-morbid chronic fatigue syndrome as compared to controls, that 
could not be explained by reduced CBFv. (83) In patients with chronic fatigue syndrome with  
POTS, Stewart et al found that CBF failed to increase with cognitive activity during orthostatic 
stress while vasomotor tone remained elevated, suggesting an uncoupling of the 
neurovascular unit. (170) During progressive orthostasis in POTS patients, increasing 
oscillatory CBF has been shown to be associated with memory deterioration and reduced 
neurovascular coupling. (82)  
 
While the above studies have elegantly highlighted the complexities of cerebral 
hemodynamic response during orthostatic stress in relation to cognitive function in individuals 
with POTS, the extent to which these findings could be attributable to chronic fatigue 
syndrome is not known. (160) Further, it remains unclear whether patients with POTS have 
the capacity to increase cerebral perfusion in response to increased cerebral metabolic 
demand in the absence of orthostatic stress. Others have shown that POTS individuals 
encounter cognitive difficulties even when recumbent. (161) In a recent study, we found 
short-term memory and alertness were impaired in POTS patients whilst seated, despite 
demonstrating similar CBFv response to transient visual stimuli in the posterior cerebral artery 
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when compared with healthy controls. (11) The current study provides additional insights 
towards cognitive dysfunction in the POTS population. Our findings suggest that in response 
to sustained cognitive demand, patients with POTS demonstrate reduction in CBFv to a similar 
degree as during orthostatic stress. Furthermore, these changes in CBFv during PCST in the 
POTS group were seen in conjunction with reduced psychomotor speed and subsequent  
 
increase in orthostatic symptom severity as compared to heathy controls. These are in keeping 
with a previous study in which deficits in selective attention, cognitive processing, and 
executive function were demonstrated in patients with POTS undertaking cognitive 
assessment whilst seated. (161)  
 
Clinical implications 
 Our findings lend further strength to the concept that cognitive dysfunction in POTS 
represents a consequence of the disease pathophysiology. However, further studies are 
needed to delineate the mechanisms underlying these observations. The use of TCD to 
measure CBF in the middle cerebral artery has been validated against functional magnetic 
resonance imaging measures of flow velocities, however, TCD requires a high level of 
experience to obtain consistently high-quality measures. (171) Nevertheless, TCD measures 
of CBF may be used as an objective tool to quantitate physiologic states in relation to objective 
cognitive and psychological assessments in clinical practice. (10) Whether reduced CBF is a 
useful biomarker in the management of POTS remains to be determined. 
 




 TCD measures CBFv as opposed to CBF. The measures are only equivalent if the vessel 
diameter does not vary. We did not assess middle cerebral artery diameter during the study, 
but others have previously observed only minor changes (<4%) in its diameter in response to 
hypocapnia and changes in blood pressure. (172) We measured CBFv to the dominant cerebral 
hemisphere. While there is evidence that CBF is comparable between hemispheres during 
orthostatic stress,(83) CBF may vary between hemispheres during cognitive tasks. (173)   
 
Undertaking the study with participants in a supine position would have removed the degree 
of orthostatic stress associated with sitting but would have hampered performance of the 
PCST and introduced additional noise to CBFv recordings. The use of fludrocortisone and rate 
control agents in some of the POTS group may have prevented the increase in heart rate with 
orthostatic stress and altered CBF responses to cognitive stress. However, withholding these 
agents could result in rebound tachycardia and exacerbation of symptoms that could modify 




Reduced cerebral blood flow and cognitive dysfunction were evident in POTS patients 
following prolonged cognitive stress in the seated position. The commonly described 
symptom of brain fog in POTS is likely attributable to the underlying disease pathophysiology 
which remains poorly understood.    
 




Chapter 5: Effect of Midodrine on Cognition and Cerebral Blood Flow 
in Postural Orthostatic Tachycardia Syndrome  
 
Contextual Statement 
 In this chapter the effect of midodrine on symptom, cognition and CBFv are 
described. Patients who reported a reduction in their symptoms following administration of 
midodrine were selected for this study in order to determine if symptomatic improvement 
was accompanied by improved CBF dynamics during orthostatic or cognitive stress. Although 
we detected some improvement in cognitive performance following the administration of 
midodrine, we were unable to associate this symptomatic improvement with a change in 
CBFv response to cognitive stress.  
 
 There are several reasons why we may have missed a true association.  Firstly, the 
period that elapsed to ensure the administered midodrine was absorbed and active resulted 
in a period during which some recovery from the baseline cognitive stress could occur. 
Therefore the repeat measure of CBFv when the cognitive protocol was repeated after the 
midodrine, whilst performed in patients who were fatigued from the previous cognitive and 
orthostatic stress, was not directly comparable to the prolonged cognitive stress in the 
protocol described in chapter 4 in which there was no rest period between repeated 
measures of RT and RVIP. Secondly, during the period midodrine was being absorbed, 
disturbance of the probe position resulted in deterioration in the quality of the TCD signal 
acquired from the MCA in some of the patients. Adjustment to improve the quality of the 
signal prior to the post midodrine baseline meant that there may have been some difference  
 
 




in angle of insonance in the MCA during the post midodrine phase of the study when 
compared with the pre-midodrine phase of the study. The value of CBFv is highly dependent 
on the angle of insonance in the blood vessel. Thus, it is the change in CBFv from the 
baseline that is used to determine the impact of cognitive challenge on CBFv however we 
cannot say for sure that the baseline from which this change was measured was not itself 
altered by the administration of midodrine. Design of future studies may overcome these 
issues by continuing the cognitive stress throughout the period of drug absorption or by 





 Postural tachycardia syndrome (POTS) is characterized by a sustained increment in 
heart rate of greater than 30 bpm within 10 minutes of standing and in the absence of postural 
hypotension that improve on adopting a recumbent posture over at least 6 months duration. 
(164) Patients with POTS often describe significant limitations in their ability to work or study 
as a result of fatigue and cognitive dysfunction, often described as “brain-fog”. (161) Our 
previous work (Chapter 4) demonstrated a significant fall in cerebral blood flow velocity (CBFv) 
of POTS participants following prolonged cognitive stress. This suggests the cognitive 
dysfunction described by patients with POTS may reflect an inability to maintain adequate CBF 
to match the increased cerebral metabolic demands of prolonged cognitive activity.  
 
 Management of POTS includes a variety of lifestyle measures and pharmacological 
agents targeted at reducing heart rate, increasing exercise tolerance, intravascular volume 
and vascular tone that have been shown to achieve only moderate efficacy. (109) Specifically,  
 




midodrine is thought to increase vascular resistance directly through activation of peripheral 
adrenergic receptors. (174) It does not cross the blood brain barrier but may be effective in 
the sub-group of POTS patients in whom venous pooling in peripheral or splanchnic 
circulations can result in reduced venous return. (13),(138) Its efficacy in POTS was estimated 
at 65% with data stemming primarily from limited studies in paediatric patients. (9) However, 
the effect of midodrine on physiologic measures remain lacking with some data showing 
reduced heart rate increment on orthostatic stress, no changes in resting systemic blood 
pressure levels but no data on CBF. (23),(139) Here, we hypothesized that midodrine improves 
cognitive performance and augments CBF  response to orthostatic and cognitive stress, and 




 We evaluated cognitive and hemodynamic responses (cardiovascular and cerebral) 
before and after midodrine (a highly bioavailable product with a peak plasma concentration 
of the prodrug and its metabolites between 30 to 60 minutes) administration in consecutively 
enrolled participants with POTS who provided written informed consent for this study. All 
physiologic measurements and cognitive assessments were undertaken at baseline during 
rest and during cognitive testing whilst seated as well as with 5-minute standing test 
(orthostatic stress). These measurements were repeated at least 30 minutes after ingestion 
of midodrine (Figure 1).  This study was approved by the institutional human research ethics 













Sequence of physiologic and cognitive measurements during the entire study protocol.  
RT: reaction time, RVIP: rapid visual information processing, OHQ: orthostatic hypotension 
questionnaire,  
COMPASS-31: Composite Autonomic Symptom Score-31, MSA-QoL: Multiple System 
Atrophy-Quality of Life. 
 
Study eligibility and enrolment  
 POTS individuals were enrolled from our autonomic clinic, where specific clinical 
criteria were met: symptoms produced by upright posture with resolution when recumbent 
for at least 6 months in duration, as well as documentation of a sustained increment of heart 
rate of >30 bpm during HUT or within 10 minutes of standing, without a postural blood  
 




pressure drop of >20 mmHg. These symptoms included light-headedness, headache, fatigue, 
neurocognitive deficits, palpitations, nausea, altered vision, shortness of breath, or sensation 
of heat while upright, with no other medical explanation for the symptoms. All POTS patients 
were on treatment in accordance with current guidelines. Participants were included in this 
study if they were taking midodrine for treatment of POTS. (109) There were no exclusion 
criteria.  
 
Patient preparation  
 All testing sessions were performed in the morning, with patients abstaining from 
alcohol and caffeine over the preceding 24 hours. All patients had been on stable medical 
therapy for POTS with no medication changes during the preceding month. Participants were 
permitted to continue all their usual medications except for vasopressors. Their usual morning 
dose of midodrine (α-adrenergic agonist, half-life of 3 hours) was withheld on the day of the 
study, allowing an interval of at least 15 hours (5x half-life) to elapse from the last dose, to 
avoid exogenous vasopressor therapy confounding interpretation of the study results. The 
study protocol was performed in a climate-controlled facility (22°C), with participants seated 
at a desk, emulating normal (school or clerical) working conditions.  
 
Study protocol 
 Physiologic measurements included electrocardiogram (ECG), heart rate (HR), blood 
pressure (BP), respiratory rate and end-tidal carbon dioxide (ETCO2). A single-lead ECG (FE132 
Bioamp, ADInstruments Pty Ltd, Sydney, Australia) was placed for continuous ECG monitoring. 
Continuous, non-invasive beat-to-beat hemodynamics (HR & BP) were also obtained using a  
 




cuff placed on the finger (photoplethysmography; Finapres Medical Systems BV, Enschede, 
The Netherlands). A chest wall strain gauge (MLT 1132/D Piezo Respiratory Belt Transducer, 
ADInstruments) was used to measure respiratory rate. ETCO2 was measured (Capnostream 
20P, Medtronic, Minneapolis, MN, USA) via nasal prongs with mouth scoop (Smart CapnoLine  
Plus, Microstream, Medtronic). Data were exported to MATLAB (MathWorks, Natick, USA) for 
analysis.  
 
We used transcranial doppler (TCD) to measure CBFv from the middle cerebral artery 
(MCA) of the dominant hemisphere (Doppler-BoxX, Compumedics DWL, Singen, Germany). A 
2-MHz transducer probe (sample rate 100 Hz, PW, Compumedics DWL) was positioned with 
an adjustable headset (DiaMon, Compumedics DWL) on the subject’s temporal bone 
(transtemporal window) to minimize movement of the probe during the study protocol. The 
envelope of the CBFv Doppler wave and all other physiologic measurements were 
simultaneously recorded with a data acquisition device (PL35/16; Powerlab, ADInstruments) 
and exported to MATLAB (MathWorks, Natick, MA, USA) for data analysis.   
 
We performed cognitive testing using an iPad-based (Apple Inc, Cupertino, CA, USA) 
software collection tool (Cambridge Neuropsychological Test Automated Battery; CANTAB® 
2019 version, Cambridge Cognition, Cambridge, UK). Specifically, we assessed the cognitive 
domains of attention and psychomotor speed by measuring rapid visual information 
processing (RVIP) reaction time (RT). The RT test provides an assessment of both the speed of 
motor and mental response. Here, we measured the time taken to release an on-screen 
button in response to a programmed visual stimulus. The RVIP test provides a measure of  
 




sustained attention. The test assesses the ability and speed of the subject to identify a target 
sequence from a series of numbers that flash up in a pseudo-random order onto the iPad 
screen at a rate of 100 numbers per minute. Here, we measured the number of correct 
responses within 8 minutes. 
 
Lastly, all participants completed the MSA-QoL (Quality of life assessment in Multiple 
System Atrophy) questionnaires to assess baseline quality of life measures. (168) Although not 
specifically designed for POTS, it has been well validated as a patient reported outcomes tool.  
Autonomic symptoms at baseline were assessed using the well validated, abbreviated 
Composite Autonomic Symptom Score (COMPASS- 31). (47) Further, in order to assess acute 
changes in symptoms with midodrine, we asked participants to rate their orthostatic 
symptoms taken from the Orthostatic Hypotension Questionnaire (OHQ). (49) The symptoms 
we assessed were dizziness, light-headedness or feeling faint; problems with vision (blurring, 
seeing spots, tunnel vision); weakness; fatigue; trouble concentrating; and head and neck 
discomfort. While the OHQ refers to symptoms experienced over the preceding week, we 
adapted it to assess immediate symptoms.    
 
Statistical analysis 
 Continuous variables were presented as mean ± standard deviation while categorical 
variables were expressed as numbers and percentages. Non-normally distributed data were 
expressed as median and interquartile range (Q1, Q3). We used averaged physiologic data 
over 30 seconds at the following time points for comparison: at baseline whilst seated and 
>30 minutes after midodrine ingestion, whilst undertaking the cognitive tasks at before and  
 




>30 minutes after midodrine ingestion in the seated position, and during the 5-minute stand 
test before and >30minutes after midodrine ingestion. A mixed effects model was used to 
assess intervention (baseline vs. midodrine) and condition (during cognitive testing and during 
orthostatic stress) as main effects and interaction between intervention and condition. 
Individual patient was modeled as random effect to account for repeated measures within 
individuals following midodrine ingestion. Model residuals were visually inspected for 
normality to ensure an appropriate model fit. Statistical tests were performed using SPSS 





 Ten participants were enrolled with a mean age of 24±8 years. The majority of 
participants were female (n=9, 90%), all of whom were taking midodrine 2.5-10mg [median 
5mg (IQR: 5, 10)] three times daily on a regular basis. Medication usage (aside from midodrine) 
are shown in Table 5.1. Self-reported symptom severity and quality of life scores (Table 1) 
demonstrate poor quality of life [(overall MSA-QoL 49 (32, 57)] and significant autonomic 












Table 5.1: Patient characteristics 
Patient characteristics 
Age, yrs 24 ± 8 
Female, n (%) 9 (90) 








Patient symptom scores: median (Q1, Q3) 
MSA-QoL 49 (32, 57) 
COMPASS-31 28 (39, 59) 
 
 
Legend Table 5.1: Patient characteristics 
POTS: postural tachycardia syndrome, BP: blood pressure, ETCO2: end-tidal carbon dioxide, CBFv: 
cerebral blood flow velocity, COMPASS-31: Composite Autonomic Symptom Score-31, MSA-QoL: 
Multiple System Atrophy-Quality of Life. 
The COMPASS-31 (adjusted) score is a validated score calculated from the raw COMPASS-31 score 
after applying a weighting that takes into account the number of points and relative importance of 
organ systems to the assessment of autonomic dysfunction. (47) A high score indicates greater severity 
of symptoms related to autonomic dysfunction. The MSA-QoL score assesses factors that impact on 













Physiologic and cognitive measurements during cognitive testing pre- and post-midodrine 
 Mean HR was consistently slower post-midodrine (p=0.001) although no significant 
changes were seen with cognitive testing, and midodrine did not impact on HR with cognitive 
testing (p=0.2, Table 5.2 & Figure 5.2B). Systolic BP increased (p=0.01) and diastolic BP showed 
an upward trend with cognitive testing (p=0.09), but midodrine did not affect either systolic 
or diastolic BP nor did it impact on the degree of increase in both systolic and diastolic BP with 
cognitive testing (both p=0.4, Table 5.2, Figure 5.2C & D). There were no changes in ETCO2 and 
CBFv with cognitive testing while midodrine use did not impact on both parameters and its 
changes with cognitive testing (both p>0.6, Table 5.2, Figure 5.2A & E). Cognitive testing 
demonstrated improved reaction time following the administration of midodrine (398±22 vs. 
431±34ms, p=0.002) although the number of correct responses with RVIP test did not change 



























Baseline cognitive  
testing 
Baseline 
 cognitive  
testing 
CBFv (cm/s) 63.9±11.1  63.7±11.7 64.0±11.4 65.5±10.6 0.6 
Heart rate (bpm) 91±15  90±14 81±18 85±20 0.2 
Systolic BP (mmHg) 110±13 121±23 114±15 120±13 0.4 
Diastolic BP (mmHg)  77±10 85±19 77±12 80±13 0.4 
ETCO2 (mmHg) 34±5 34±5 33±4 34±4 0.7 
RVIP (no. correct 
responses) 
- 34±9 - 39±12 0.16 
Reaction time (ms) - 431±34 - 398±22 0.002 
 
P value denotes comparison between pre-midodrine and post-midodrine 
response to cognitive stress, POTS: postural tachycardia syndrome, CBFv: 
cerebral blood flow velocity, BP: blood pressure, ETCO2: end-tidal carbon 
dioxide, RVIP: rapid visual information processing, no.: number. Data are 
presented as mean ± standard deviation or median (Q1, Q3). OHSA: Orthostatic 
Hypotension Symptom Assessment, OHQ: Orthostatic Hypotension 
Questionnaire. OHSA is the symptom assessment component of the OHQ 
questionnaire used to quantify symptoms present at the time the questionnaire 
was completed.(49) Six symptoms are given a score from 0 (symptom not 
present) to 10 (most severe), with a maximum total score of 60. 
 
 




Figure 5.2: Physiologic measurements pre- and post-midodrine with cognitive test & 
orthostatic stress 
 





Legend Figure 5.2: Physiologic measurements pre- and post-midodrine with cognitive test & 
orthostatic stress 
 
The p values in each graph denote comparisons for ^condition (baseline vs. cognitive test or 
baseline vs. orthostatic stress) in both groups, ~group (pre- vs. post-midodrine) and 
#interaction (between condition and group). For ease of illustration, all values plotted are 
mean ± standard error of the mean with uni-directional error bars 
 
 
Physiologic measurements during orthostatic stress pre- and post-midodrine 
 Orthostatic stress resulted in reduced CBFv (p=0.03, Figure 2A), increased HR (p<0.001, 
Figure 2B), systolic (p=0.008, Figure 5.2C) and diastolic BP (p=0.001, Figure 5.2D) while ETCO2 
remained unchanged (p=0.3, Figure 5.2E). Mean HR was consistently lower while all other 
physiologic parameters (including CBFv) remain unchanged post-midodrine. Further, 
midodrine had no impact on the degree of change in all physiologic parameters with 

































63.9±11.1 59.7±11.9 64.0±11.4 59.3±10.3 0.7 
Heart rate 
(bpm) 
91±15 104±21 81±18 96±25 0.4 
Systolic BP 
(mmHg) 
110±13 125± 26 114±15 124±15 0.6 
Diastolic BP 
(mmHg)  
77±10 93±21 77±12 90±18 0.6 
ETCO2  
(mmHg) 
34±5 33±3 33±4 32±4 1.0 
 
P value denotes comparison between pre- and post-midodrine from 
baseline to post orthostatic stress. POTS: postural tachycardia syndrome, 
CBFv: cerebral blood flow velocity, BP: blood pressure, ETCO2: end-tidal 
carbon dioxide. All data are presented as mean ± standard deviation.  
 





Orthostatic symptom assessment 
 Following the administration of midodrine, orthostatic symptoms score from OHQ 
improved significantly [36 (IQR: 26, 38) vs. 23 (11, 24); p <0.001]. 
 
Discussion   
 
 In this study, comprehensive physiologic measurements in patients with POTS showed 
that midodrine exerted a consistent HR lowering effect while orthostatic stress resulted in 
significant increase in blood pressure and HR. We did not demonstrate significant changes in 
physiologic parameters attributable to midodrine administration when the POTS patients 
were subjected to cognitive testing or orthostatic stress. Despite the lack of impact on CBFv 
within 1 hour of midodrine administration, there was an improvement in patient reported 
orthostatic symptoms as well as improved psychomotor speed.  
 
The POTS patients in our study reported a significant symptom burden and reduced 
quality of life consistent with previous studies. (175) Improvement in symptoms has been 
reported previously in POTS patients following regular midodrine therapy,(176) and during 
head-up tilt test following a single dose of midodrine,(54) however objective physiologic 
evidence for the use of midodrine in the management of POTS is limited. (9) Individual studies 
have shown that midodrine use conferred blood pressure increase in hypotensive cohorts 
with idiopathic hypotension, spinal cord injury, and neurogenic hypotension, (177),(178, 179) 
but a meta-analysis of all studies in which the effect of midodrine on blood pressure was 
studied in hypotensive cohorts did not find a statistically significant effect on BP following the  
 




administration of midodrine(180) and no effect on BP was noted following midodrine 
administration in a normotensive control group during a study of individuals with spinal cord 
injury and able bodied controls. (181) In POTS patients, the effects of midodrine include 
reduced heart rate increment on orthostatic stress and no changes in resting systemic blood 
pressure levels. (23),(139) Our data affirms the heart rate lowering effect of midodrine in POTS 
that has been previously reported. Studies measuring the effect of midodrine on CBFv 
response to cognitive activation have generated conflicting results. In a group of patients with 
spinal cord injury, and in a control group, midodrine did not alter the CBFv response to a serial 
subtraction task. (181) Others have reported that midodrine resulted in a greater increment 
in CBFv to a brief RT task than was seen following placebo in patients with chronic 
hypotension. (177) This study provides new information on midodrine use in patients with 
POTS where there is a lack of impact on CBFv whilst undertaking cognitive testing and with 5 
minutes of orthostatic stress within 1 hour of dosing.  
 
An increase in regional CBFv generally accompanies cognitive activation, with 
increased delivery of oxygen and nutrients to the metabolically active cells. (182),(183) Others 
have associated hypotension with a reduced capacity to increase CBF in response to a reaction 
task,(177) and lower CBFv during a working  memory task. (182) Our subjects’ BP was higher 
during cognitive testing and it remains unclear why the increase in CBFv was not observed in 
our POTS patients. At the same time, it is unlikely that the cognitive improvements can be 
explained by the HR lowering effect of midodrine alone. It is possible that either the midodrine 
dose administered was insufficient or the effect of midodrine on CBFv was longer than the 
window we anticipated. 
 






 This study has small sample size which could have contributed to some of the negative 
findings. However, in the absence of published data on the impact of midodrine on CBFv, 
statistical powering could not be undertaken. TCD measures CBF velocity, as opposed to CBF. 
The measures are only equivalent if the vessel diameter does not vary. We did not assess MCA 
diameter during the study, but others have previously observed only minor changes (<4%) in 
diameter of the MCA in response to hypocapnia and changes in BP. (172) We measured CBFv 
in the MCA from the dominant cerebral hemisphere only. While there is some evidence that 
CBF may be comparable between hemispheres during orthostatic stress,(83) CBF may vary 
between hemispheres during cognitive testing. (173),(184) Without a placebo controlled arm,  
it is not possible to attribute improvement in symptoms and cognitive function to midodrine 
alone. Repeated physiologic measurements at additional time-points might have provided us 
with further insights on the potential effect of midodrine on cerebral perfusion. The use of 
fludrocortisone and HR lowering agents may have altered our patients’ CBF and systemic 
hemodynamic responses to cognitive and orthostatic stress. However, withholding these 
agents could also result in rebound tachycardia and exacerbation of symptoms that may 
impact on various physiologic parameters. It remains unclear whether the physiologic impact 
of midodrine would differ in different POTS subtypes with peripheral venous pooling or low 













Acute administration of midodrine in POTS resulted in improved orthostatic symptoms and 
cognitive function despite a lack of impact on cerebral perfusion during cognitive testing and 
orthostatic stress within the first hour. Further studies are needed to further delineate the 
mechanisms responsible for the symptomatic benefits with its use.  
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 In Chapter 1 the heterogeneity in the pathophysiological underpinnings of POTS was 
described, along with the results of a number of studies in which the presence of 
autoantibodies had been detected in the plasma of patients with POTS. (185),(129) Although 
plasma exchange is traditionally utilised in the treatment of patients with an identified 
antibody, the process of plasma exchange does not require the identification of the causative 
antibody (in contrast to therapeutic approaches  involving absorption or neutralisation of 
antibodies). When there is suspicion that an auto-antibody may be driving the pathologic 
process, there may be value in exchanging plasma with albumin in order to assess 
symptomatic response following removal of pathologic autoantibodies. In this manuscript we 
describe this approach in a patient with POTS.  
 
 In this case, the patient described symptomatic improvement following an initial 2 
week period, involving 5 discrete episodes of plasma exchange, despite a greater increment  
in HR in response to orthostatic challenge performed after plasma exchange. Since symptom 
severity is not necessarily correlated with HR in patients with POTS, and HR response to 
orthostatic stress may vary from day to day, we did not exclude the possibility that plasma 
exchange had removed a pathologic autoantibody. However we had no objective biological 
measure to validate the subjective improvement in patient symptom scores. After a poor 
response to alternative therapeutic approaches (including repeated infusion of normal saline 
and a 6 month trial of azathioprine), a multi- disciplinary team agreed to a further period of 
therapeutic plasma exchange for this patient.  We studied CBFv responses to orthostatic and 
cognitive stress in this patient to determine if there might be a correlation between this  
 




objective measure and her symptom score. In the case report below, we describe the results 
of CBFv responses to orthostatic and cognitive stress performed approximately 12 months 
after the patient had commenced maintenance therapeutic plasma exchange at 
approximately monthly intervals. The baseline measures were assessed on the day prior to 
one of her plasma exchange treatments, and the post treatment assessment was performed 
3 days after the plasma exchange therapy. The timing of the post treatment assessments was 
based on the patient’s experience that day 3 post plasma exchange was usually when 
symptomatic response was maximal, as the process of plasma exchange itself often resulted 
in fatigue for several days. 
 
  In total, five patients with symptoms associated with POTS have undergone plasma 
exchange at the Royal Adelaide Hospital. In each case, induction plasma exchange was offered 
after informed consent was given. The approach consisted of 5 cycles of plasma exchange over 
a period of 2 weeks. Two patients did not describe a significant improvement in symptoms or 
hemodynamic parameters following the induction therapy and no further plasma exchange 
was undertaken. In addition to the case reported below, 2 other young women resistant to or 
intolerant of the usual therapeutic modalities for POTS reported improvement following 
induction plasma exchange therapy.  A period of maintenance plasma exchange therapy was 
provided for these 2 patients, however infection of the intravascular device in one patient, 
and the short duration (less than 2 weeks) of benefit following each session in both patients, 
lead to a decision to abandon this approach in both patients.  Overall, our experience with 
plasma exchange therapy in patients with POTS has been disappointing.  
 
 







 A 32 year-old female developed severe orthostatic intolerance associated with fatigue 
and cognitive difficulties following an episode of shingles in 2015. She had pre-existing medical 
co-morbidities of Crohn’s disease, joint hypermobility, gastroesophageal reflux and 
narcolepsy. Standing test resulted in light-headedness with acrocyanosis of her extremities 
within 5 minutes and significant heart rate increase from 77 to 110 bpm without any blood 
pressure drop, indicative of POTS. Routine blood investigations were largely unremarkable. 
Autoimmune assays, immunoglobulins, complement and plasma noradrenaline levels were 
also normal. Her symptoms of presyncope, palpitations, nausea, headache, fatigue and 
exercise intolerance were refractory to standard interventions including increasing salt and 
water intake, fludrocortisone and propranolol over a 12-month period.  
  
 A trial of plasma exchange as immunomodulatory therapy was undertaken with 
informed consent, involving exchange of 3 litres of plasma with 4% albumin over 2-4 hours on 
six occasions over a 2-week period. Her symptom improvement following plasma exchange 
was assessed with questionnaires (Table 6.1): almost 40% improvement in The Composite 
Autonomic Symptom Score (COMPASS 31) (benefits seen in several domains); 38% 
improvement in orthostatic hypotension symptom assessment (OHSA) score; and 29% 
improvement in orthostatic hypotension daily activity scale (OHDAS) (Table 6.1). Further, 
neuropsychological assessment with CANTAB (Cambridge neuropsychological test automated 
battery) showed slight improvement in attention, alertness and memory (Table 6.1). However,  
 
 




there was no improvement in biological parameters during a 10-minute tilt-table test 
performed 3 days after completion of the 2-week plasma exchange (Table 6.1). 
  
 The patient’s symptoms returned 4 weeks after cessation of plasma exchange. Over 
the subsequent 5 months, there was no improvement in symptoms despite regular 
intravenous normal saline infusions and oral azathioprine. Eventually maintenance plasma 
exchange was recommenced at two to four weekly intervals. Reassessment of symptom 
scores, and responses to orthostatic and cognitive assessment after approximately 12 months 
of therapy are reported in Table 6.1 (far right column). Improved positional hemodynamics 
including cerebral blood flow after cognitive challenge (CANTAB: rapid visual information 
processing test) at three days after versus one day prior to plasma exchange (Figure 6.1). Our 
patient’s positive response to plasma exchange remains durable with maintenance plasma 
exchange sessions for more than 18 months through peripheral intravenous cannula with no 




 Others have reported favourable outcomes of plasma exchange in immune mediated 
conditions such as autoimmune autonomic ganglionopathy, Guillain-Barré syndrome, 
myasthenia gravis and idiopathic thrombotic thrombocytopenic purpura. We posit that the 
removal of auto-antibodies may underscore the beneficial effects of plasma exchange in POTS. 
There has been one other report of shorter term immunomodulatory therapy involving 
prednisolone and plasmapheresis in a patient who developed POTS after human 
papillomavirus vaccination. (186) The technique of plasma exchange is considered to be of  
 




sufficiently low risk with extensive experience to date in healthy donors and without any risk 
of serious or fatal consequences from conventional immunomodulating agents. The positive  
outcome of our case with long-term plasma exchange calls for further studies to define the 
immune-based mechanisms that may be responsible for this chronic debilitating condition.  
Table 6.1: Response to acute and chronic plasma exchange in a patient with POTS 
 
 






Figure 6.1: Hemodynamic and cerebral blood flow changes in a patient treated with chronic 
plasma exchange therapy 
The attenuation in cerebral blood flow velocity profile with cognitive challenge (top 
left) was ameliorated following plasma exchange (top right). Pulse pressure (shaded 
bars, bottom left) was marginally higher after plasma exchange whilst seated, standing 
and with cognitive challenge. Heart rate (bottom right) was consistently lower after 




 The utility of measuring CBFv response to orthostatic and cognitive challenge in 
patients with POTS requires further validation, however in this case the improvement in CBFv 






 During the course of this work, I highlighted the paucity of evidence for the current 
treatment modalities utilised in the management of patients with POTS. The heterogeneity of 
the underlying pathophysiology driving the physiological changes in POTS was highlighted and 
the need for an objective measure of treatment response was emphasized.  Recognizing the 
subjectivity of symptom questionnaires and the discordance of symptom severity and HR control 
in this patient group, the value of TCD as an objective measure of CBFv during orthostatic and 
prolonged cognitive assessment was studied.  
 
 Firstly, in chapter 3 I describe the results of a pilot study in which the use of a portable 
ultrasound machine was used to measure responses in CBFv to a brief visual stimulus in patients 
with POTS and healthy controls. During this study, cognitive assessment was also undertaken. 
This is followed, in Chapter 4, by the description of a larger study in which headgear fixation of a 
probe and a physiological laboratory setup allowed for recording of hemodynamic and CBFv 
recording during orthostatic and prolonged cognitive stress in POTS patients and healthy 
controls. 
 
 Although the POTS group had slower reaction times and lower accuracy in cognitive 
challenges in this study, we found similar responses to those seen in the control group in both 
hemodynamic and CBFv responses to a 5 minute stand test and to a brief cognitive challenge.  A 





was prolonged, however, with a greater decline in CBFv relative to the earlier cognitive 
assessment seen in the POTS group. The increase in symptoms from baseline to the end of this 
study was significantly greater in the POTS group.  
 
 Many patients with POTS describe significant symptomatic improvement with midodrine 
therapy. Thus, in chapter 5 there follows a description of my work in which I explored the 
hypothesis that vasopressor therapy might be exerting some effect on CBFv response to cognitive 
stress, despite the fact that it does not cross the blood brain barrier.  The study involved TCD 
measures of CBFv responses to cognitive and orthostatic stress both before and after the 
administration of midodrine.  No evidence for change in CBFv in response to either orthostatic 
or cognitive stress following administration of midodrine was detected despite the reduction in 
symptoms and improvement in reaction time seen when the cognitive assessments was repeated 
following the administration of midodrine. It is possible this negative finding reflects the small 
number of patients in the study or technical issues with the study design. The significant 
improvement in reaction time in the assessment performed after the administration of 
midodrine suggests that, unfortunately, the sensitivity of TCD as a measure of CBFv response to 
orthostatic and cognitive stress may not be adequate to utilise as an endpoint in clinical trials.  
 
 In Chapter 6 I have described the use of TCD to monitor the effect of a novel therapeutic 
intervention, plasma exchange, on CBFv in a patient with POTS. Plasma exchange has been used 





are thought to play a critical role. Generally, conditions in which plasma exchange therapy is a 
recognized therapeutic approach an assay for the causative auto-antibody is available. This is not  
the case in POTS, despite reports of antibodies targeting adrenergic, cholinergic or cardiac lipid 
proteins present in the plasma of patients with POTS. The potential for immunotherapy is 
therefore appealing but carries with it significant risk of adverse events. In our patient, 
symptomatic improvement was associated with a reduction of HR increment to both orthostatic 
and cognitive stress, and a suggestion that CBFv was improved during cognitive assessment 
following plasma exchange when compared to the CBFv response during cognitive assessment 
prior to plasma exchange.  
 
Overall, our studies of CBFv responses to orthostatic and cognitive challenges, whilst providing 
some indication that CBFv may deteriorate with prolonged cognitive stress in patients with POTS, 
did not correlate well with symptom severity. Whilst TCD is a useful tool to study the changes in 
CBFv associated with brainfog, a search for alternative biologic assays are needed to support the 
future assessment of novel therapeutic interventions in the management of POTS. 
 
Future directions for study 
 
  Until a biomarker is identified which provides a meaningful correlation between 
symptom severity and pathophysiology in patients with POTS, interpretation of therapeutic 
efficacy for novel treatment approaches will require large placebo-controlled, randomised 
clinical trials to compensate for the impact of the significant placebo effect associated with 




provide some hope in the future for diagnostic and therapeutic options for patients with POTS.  
Whilst plasma exchange therapy in patients with POTS seems unlikely to play a great role, the 
demonstration of auto-antibodies with adrenergic activity in plasma collected from patients with 
POTS suggests that, in some patients, immune-mediated approaches may yet have a role. Not 
covered in detail in this thesis but noted as a potential future direction of research is the 
exploration of the role of NET activity, and with it, the possibility of intervening in NET function. 
 
The high prevalence of “brainfog” in patients with POTS, however, makes CBF an area that 
warrants further research. An alternative technique to measure regional CBF, such as functional 
magnetic resonance imaging (fMRI), may prove valuable in these patients. Although tilt tests and 
prolonged cognitive protocols are impractical when studying CBF using fMRI, it may be possible 
to replicate many of the physiological changes associated with orthostatic stress through the use 
of lower body negative pressure.  
 
Ultimately, the heterogeneity of the condition is a huge barrier to progress in our understanding 
of POTS. Progress in this condition may come only through piecemeal approaches, each 
applicable to only a small percentage of the patients with unique variations in physiological 
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